

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 568 833 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 93105829.1

(51) Int. Cl.⁵: **C07K 15/00, A61K 37/64,
C12N 15/15**

(22) Date of filing: 08.04.93

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(30) Priority: 10.04.92 JP 90488/92
22.02.93 JP 31855/93(43) Date of publication of application:
10.11.93 Bulletin 93/45(84) Designated Contracting States:
AT BE CH DE DK ES FR GB IT LI NL SE(71) Applicant: Eisai Co., Ltd.
6-10, Koishikawa 4-chome
Bunkyo-ku
Tokyo(JP)(72) Inventor: Kato, Hiroyuki
25-41, Goshogaoka 5-chome,
Moriyamachi
Kitasouma-gun, Ibaraki(JP)
Inventor: Yoshitake, Shinji
5-61, Ninomiya 4-chome

Tsukuba-shi, Ibaraki(JP)
Inventor: Suzuki, Suguru
1, Kariyacho 2-chome
Ushiku-shi, Ibaraki(JP)
Inventor: Suzuki, Noboru
33-24, Umezono 2-chome
Tsukuba-shi, Ibaraki(JP)
Inventor: Seto, Toshio
160-2, Sakaecho 3-chome
Ushiku-shi, Ibaraki(JP)
Inventor: Nagaoka, Naoko
1830-1, Kaneda
Tsukuba-shi, Ibaraki(JP)
Inventor: Mizui, Yoshiharu
9-10, Matsushiro 4-chome
Tsukuba-shi, Ibaraki(JP)

(74) Representative: Hansen, Bernd, Dr.
Dipl.-Chem. et al
Hoffmann, Eitle & Partner
Patent- und Rechtsanwälte,
Postfach 81 04 20
D-81904 München (DE)(54) **Human antithrombin III mutants.**

(57) A novel human antithrombin III (AT III) mutant having a high antithrombin activity in the absence of heparin and effective in the treatment of thrombotic disorders as an anticoagulant, which is obtained by mutating amino acids at the reactive site and the heparin binding site of human AT III into another amino acids with the use of the recombinant DNA technology with the use of a DNA coding for AT III as a template.

A method for mass producing the above-described mutant by incubating a host transformed by an expression vector having the cDNA of the mutant inserted therein.

Background of the Invention

Field of the Invention

- 5 The present invention relates to a human antithrombin III (AT III) mutants which are obtained by mutating one or more amino acid(s) in the amino acid sequence of human AT III into another amino acid(s) and exhibit high antiprotease activities even in the absence of heparin. These human AT III mutants are usable as a remedy for thrombotic disorders.

10 Description of the Related Art

Anticoagulant activity of glycosaminoglycans including heparin is mediated by antithrombin III (AT III) and heparin cofactor II (HC II) contained in the blood. AT III and HC II are serine protease inhibitors which are called serpins in general. There has been often reported with respect to AT III among these substances
15 that a decrease in the blood AT III level due to a congenital or acquired factor would result in thrombotic disorders. Accordingly, AT III plays a physiologically important role as a factor regulating the blood coagulation system consisting of a series of serine proteases.

It is known that human AT III is a glycoprotein of a molecular weight of approximately 60 kd which is mainly synthesized in the liver and contained in normal plasma at a concentration of about 150 μ g/ml and
20 that human AT III inhibits serine proteases participating in coagulation and fibrinolysis systems including thrombin and factor Xa. The primary structure of human AT III has been clarified by the direct determination of its amino acid sequence (see Petersen, T.E. et al., *The Physiological Inhibitors of Blood Coagulation and Fibrinolysis*, Elsevier Science Publishers, Amsterdam, 43, 1979) and cDNA cloning [see Bock, S.C. et al.,
25 *Nucl. Acids Res.*, 10, 8113 (1982); Prochownik, E.V. et al., *J. Biol. Chem.*, 258, 8389 (1982); Chandra, T. et al., *Proc. Natl. Acad. Sci. USA*, 80, 1845 (1983)]. According to these reports, human AT III is a single-chain glycoprotein consisting of 432 amino acids which is secreted and formed by excising a signal peptide of 32 residues from a precursor protein. It has four N-linked glycosylation sites in the molecule. The carbohydrate content is about 15% of the molecular weight.

Human AT III reacts with a serine protease such as thrombin at a ratio of 1 : 1 and thus forms a stable
30 complex, thus inhibiting the activity of the protease. It is thought that, in this reaction, a peptide bond between the 393rd Arg residue and the 394th Ser residue in the molecule of human AT III is cleaved by the protease and an acyl bond is formed between the terminal Arg residue newly formed and the Ser residue at the active center of the protease. This Arg (393)-Ser (394) sequence is generally referred to as a reactive site.

The protease inhibition by AT III would relatively slowly proceed. When the reaction system contains
35 heparin, however, the reaction is dramatically accelerated. Namely, the addition of heparin elevates the thrombin inhibition rate of AT III by more than 1,000 times. It is thought that this function mechanism proceeds as follows. When heparin binds to a specified site (heparin binding site) in AT III, the higher-order structure of AT III turns into a structure liable to undergo interaction with the protease. At the same time, the
40 protease binds to the heparin molecule. Thus a ternary complex is apt to be formed. Further, from the physiological viewpoint, it is considered that heparin-like substances existing on the surface of vascular endothelial cells exert similar actions and thus play an important role in the mechanism for regulating the blood coagulation system by AT III.

There have been used so-called anticoagulants for treating and preventing thrombotic disorders induced
45 by various causes. Heparin is one of highly important anticoagulants at present. However, it is reported that serious side effects are sometimes induced by the administration of heparin [see Amerena, J. et al., *Adverse Drug React. Acute Poisoning Rev.*, 9, 1 (1990); Levine, M.N. et al., *Semi. in Thrombos. Hemostas.*, 12, 39 (1986); Kelton, J.G. et al., *ibid.*, 12, 59 (1986); Levine, M.N., *ibid.*, 12, 63 (1986)]. Typical examples of these side effects include hemorrhage, thrombocytopenia, hypoadrenalism, hypersensitiveness, necrosis of
50 the administration site and osteoporosis. When there is a high risk of hemorrhage in the fields of, for example, obstetrics and gynecology or postoperative treatments or in the case of a prolonged administration, heparin should be carefully used. Furthermore, it is reported that heparin promotes inactivation of AT III by elastase of neutrophils in vitro [see Jordan, R.E. et al., *Science*, 237, 777 (1987); Jordan, R.E. et al., *J. Biol. Chem.*, 264, 10493 (1989)]. Thus care should be taken in the administration of heparin when elastase
55 of neutrophils seemingly relates to the conditions of diseases such as serious infection or septicemia. In addition, the anticoagulant effect of heparin is essentially mediated by AT III and, therefore, can be scarcely expected in the case where blood AT III level is lowered.

Meanwhile, human AT III has been clinically applied to thrombophilia based on congenital AT III deficiency and disseminated intravascular coagulation syndrome (DIC) accompanied by a decrease in AT III in the form of a plasma derived AT III concentrate. As described above, however, AT III exhibits only a slow progressive antithrombin activity in the absence of heparin. Therefore the use of AT III alone is rather a supplementary treatment and its usefulness as an anticoagulant is limited. Thus attempts have been made to use AT III together with heparin or to prepare and use an AT III/heparin complex to thereby improve the usefulness of AT III as an anticoagulant. However, it is obvious that the above-mentioned disadvantages of heparin cannot be overcome even by these methods.

As described above, AT III has two functional sites, namely, the reactive site and the heparin-binding site. A number of reports have revealed that the amino acid sequence around the reactive site carries an important role in the expression of the function as a protease inhibitor as well as in the determination of inhibition specificity against various proteases. In congenital AT III anomaly such as AT III Hamilton wherein Ala at the 382-position has mutated into Thr [see Devraj-Kizuk, R. et al., *Blood*, 72, 1518 (1988)], AT III Cambridge I wherein Ala at the 384-position has mutated into Pro [see Perry, P.J. et al., *FEBS Lett.*, 254, 174 (1989)], AT III Glasgow wherein Arg at the 393-position has mutated into His [see Erdjument, H. et al., *J. Biol. Chem.*, 263, 5589 (1988)], AT III Pescara wherein Arg at the 393-position has mutated into Pro [see Lane, D.A. et al., *J. Biol. Chem.*, 264, 10200 (1989)] and AT III Denver wherein Ser at the 394-position has mutated into Leu [see Stephens, A.W. et al., *J. Biol. Chem.*, 262, 1044 (1987)], abnormal AT III molecules each has lost antiprotease activity and patients of these anomalies suffer from thrombotic disorders.

On the other hand, studies on congenital AT III molecule anomaly and results of chemical modification of amino acid residues have revealed amino acids directly relating to the heparin-binding site, namely, binding to heparin. Regarding the molecular anomaly, there have been reported AT III Rouen III wherein Ile at the 7-position has mutated into Asn [see Brennan, S.O. et al., *FEBS Lett.*, 237, 118 (1988)], AT III Rouen IV wherein Arg at the 24-position has mutated into Cys [see Borg, J.Y. et al., *FEBS Lett.*, 266, 163 (1990)], AT III Basel wherein Pro at the 41-position has mutated into Leu [see Chang, J.Y. and Tran, T.H., *J. Biol. Chem.*, 261, 1174 (1986)], AT III Toyama wherein Arg at the 47-position has mutated into Cys [see Koide, T. et al., *Proc. Natl. Acad. Sci. USA*, 81, 289 (1984)] and AT III Geneva wherein Arg at the 129-position has mutated into Gln [see Gandrille, S. et al., *J. Biol. Chem.*, 265, 18997 (1990)]. Each of these abnormal AT IIIs has a lowered heparin affinity and cannot exert normal physiological functions, thus causing thrombotic disorders. Further, the results of experiments on chemical modification of amino acids suggest that amino acids including Trp at the 49-position, Lys at the 114-position, Lys at the 125-position, Arg at the 129-position, Lys at the 136-position and Arg at the 145-position might directly relate to binding to heparin [see Blackburn, M.N. et al., *J. Biol. Chem.*, 259, 939 (1984); Peterson, C. et al., *J. Biol. Chem.*, 262, 8061 (1987); Sun, X.J. and Chang, J.Y., *Biochemistry*, 29, 8957 (1990)].

Based on these findings, attempts have been made to improve AT III through substitution of an amino acid(s) of AT III. For example, Zettlemeissl et al. have disclosed a method for producing an AT III mutant having improved properties relating to heparin binding/heparin activation by mutating an amino acid(s) at the glycosylation site in AT III and another method for producing an AT III mutant having modified enzyme specificities by mutating an amino acid(s) at the reactive site (European Patent Publication-A No. 384122). Further, Dijkema et al. has reported a method for producing an AT III mutant having a modified antithrombin/antiXa activity by mutating an amino acid(s) at the reactive site (International Publication No. WO 91/00291).

However there has not been found out any human AT III mutant which is satisfactory from the clinical viewpoint. It is, therefore, urgently required to construct a human AT III mutant having an elevated activity of inhibiting thrombin or factor Xa in the absence of heparin.

It is an object of the present invention to provide novel human AT III mutants having a high antithrombin activity even in the absence of heparin. It is another object of the present invention to provide a method for mass producing said human AT III mutants by the recombinant DNA technology.

Disclosure of the Invention

Summary of the Invention

At present, it is thought that the mechanism of enhancing the antiprotease activity of AT III by heparin would proceed as follows. First, heparin binds to the heparin binding site of AT III to thereby change the conformation of AT III into another one which can more easily react with a protease. At the same time, the protease binds to the same heparin molecule at the above-mentioned heparin binding site, thus elevating the rate of the formation of an AT III/protease complex [see Pletcher, C.H. and Nelsestuen, G.L., *J. Biol.*

Chem., 258, 1086 (1988)]. According to this hypothesis, the change in the configuration at the reactive site induced by the heparin binding to the heparin binding site of AT III is thought to be important in the enhancement of the antiprotease activity. This fact suggests that an AT III mutant exhibiting an enhanced protease activity in the absence of heparin can be constructed by artificially modifying the amino acid sequence in the neighborhood of the reaction site to thereby change the configuration at the reactive site.

If an AT III mutant having an enhanced antithrombin activity in the absence of heparin can be obtained based on the above-mentioned idea, the action of binding to heparin is seemingly not an important characteristic of this AT III mutant. Thus it is conceivable that a reduction in the affinity for heparin caused by introducing an amino acid substitution into the heparin binding site of the above-described AT III mutant would scarcely affect its function, different from the above-mentioned AT III TOYAMA and AT III GENEVA wherein a mutation in the heparin binding site results in abnormalities in the function. It is rather expected that the clinical usefulness of AT III mutant might be enhanced thereby, since interactions with heparin-like substances existing on the surfaces of vascular endothelial cells are suppressed and thus the half-life in the blood is prolonged and the inactivation with neutrophil elastase is avoided.

Based on this idea, the present inventors have conducted extensive studies in order to improve human AT III. As a result, they have successfully constructed the desired novel human AT III mutants, thus completing the present invention.

Accordingly, the present invention relates to a human antithrombin III (AT III) mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence described in sequence ID. No. 2 except that an amino acid(s) mutates into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions, the 125- to 133-positions and the 384- to 398-positions.

Namely, the present invention relates to an AT III mutant which is a mutated human AT III characterized in that at least one amino acid in each of four regions of the 11- to 14-positions, the 41- to 47-positions, the 125- to 133-positions and the 384- to 398-positions has mutated, either singly or combinedly, into another amino acid(s), or an AT III mutant characterized in that in the amino acid sequence of human AT III, one or more amino acid(s) selected from among those at the 11- to 14-positions, the 41- to 49-positions, the 121- to 135-positions and the 384- to 398-positions have mutated into another amino acid(s) and the antithrombin activity in the absence of heparin is elevated as compared with natural AT III.

The human AT III mutant according to the present invention includes the following embodiments:

(1) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that an amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions, the 125- to 133-positions and the 384- to 398-positions mutates into another amino acid(s) selected from the group consisting of Ala, Gly, Trp, Pro, Leu, Val, Phe, Tyr, Ile, Glu, Ser, Gln, Asn and Arg.

(2) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions and that an amino acid(s) mutates into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 125- to 133-positions.

(3) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions and that an amino acid(s) mutates into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions and the 41- to 47-positions.

(4) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions and that an amino acid(s) mutates into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions and the 125- to 133-positions.

(5) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions and that an amino acid(s) mutates into another amino acid(s) at a region(s) selected from the group consisting of the 41- to 47-positions and the 125- to 133-positions.

(6) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 11- to 14-positions and that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions.

(7) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 41- to 47-positions and that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions.

(8) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 125- to 133-positions and that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions.

(9) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions.

(10) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that an amino acid(s) at the 384- to 398-positions mutates into another amino acid(s) selected from the group consisting of Ala, Pro, Leu, Val, Gly, Arg, Glu and Phe and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 125- to 133-positions.

(11) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that an amino acid(s) at the 390- to 392-positions mutates into another amino acid(s) selected from the group consisting of Ala, Pro, Leu, Val and Phe and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 125- to 133-positions.

(12) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that Gly at the 392-position mutates into Pro and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 125- to 133-positions.

(13) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that a mutation selected from the group consisting of a mutation of Ile at the 390- position into Ala, a mutation of Ala at the 391- position into Phe, Val or Leu and a mutation of Gly at the 392-position into Pro is present and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 125- to 133-positions.

(14) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that a mutation selected from the group consisting of a mutation of Ala at the 384- position into Gly, a mutation of Ala at the 387- position into Phe, a mutation of Val at the 389- position into Pro, a mutation of Pro at the 397- position into Arg and a mutation of Asn at the 398-position into Glu or Arg is present and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 125- to 133-positions.

(15) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that a mutation selected from the group consisting of a mutation of Lys at the 11- position into Ile, a mutation of Asp at the 14- position into Ser is present and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 41- to 47-positions, the 125- to 133-positions and the 384- to 398-positions.

(16) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that a mutation selected from the group consisting of a mutation of Lys at the 11- position into Ile and a mutation of Asp at the 14- position into Ser, and, another mutation selected from the group consisting of a mutation of Ile at the 390- position into Ala, a mutation of Ala at the 391- position into Phe, Val or Leu and a mutation of Gly at the 392-position into Pro are present, and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 41- to 47-positions and the 125- to 133-positions.

(17) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that a mutation selected from the group consisting of a mutation of Lys at the 125- position into Gln, a mutation of Arg at the 129- position into Gln, a mutation of Arg at the 132- position into Gln and a mutation of Lys at the 133- position into Asn or Gln is present and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 384- to 398-positions.

(18) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that a mutation selected from the group consisting of a mutation of Lys at the 125- position into Gln, a mutation of Arg at the 129- position into Gln, a mutation of Arg at the 132- position into Gln and a mutation of Lys at the 133- position into Asn or Gln, and, another mutation selected from the group consisting of a mutation of Ile at the 390- position into Ala, a mutation of Ala at the 391- position into Phe, Val or Leu and a mutation of Gly at the 392-position into Pro are present, and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group

consisting of the 11- to 14-positions and the 41- to 47-positions.

(19) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that Gly at the 392-position mutates into Pro.

5 (20) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that Ala-Gly at the 391- to 392-positions mutates into Phe-Pro.

(21) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that Ile-Ala at the 390- to 391-positions mutates into Ala-Leu.

(22) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that Lys at the 125-position mutates into Gln and Ala-Gly at the 391- to 10 392-positions mutates into Phe-Pro.

(23) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that Arg-Lys at the 132- to 133-positions mutates into Gln-Asn and Ile-Ala at the 390- to 391-positions mutates into Ala-Leu.

15 (24) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that Arg-Lys at the 132- to 133-positions mutates into Gln-Asn and Ala-Gly at the 391- to 392-positions mutates into Phe-Pro.

(25) A human AT III mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence except that Lys at the 133-position mutates into Asn and Ala-Gly at the 391- to 392-positions mutates into Phe-Pro.

20 The present invention includes human AT III mutants which are obtained by substituting an amino acid(s) constituting natural human AT III with another amino acid(s) at a desired position(s).

Each of these human AT III mutants is expressed and produced by using animal cells as a host. As will be described hereinbelow, the mutants thus obtained exhibit elevated antithrombin activities in the absence of heparin as compared with a plasma derived human AT III concentrate or a natural recombinant human 25 AT III. Further, these mutants exert improved drug efficacies in tests with the use of animals as compared with the plasma derived human AT III concentrate. Thus it is expected that they are highly useful for clinical purposes.

The present invention also relates to a DNA coding for the human AT III mutant according to the present invention, an expressible vector which has a DNA containing part or the whole of the DNA 30 sequence coding for the human AT III mutant according to the present invention, a transformant which is obtained by subjecting host cells to transformation with the above-described expressible vector and a method for producing a human AT III mutant which comprises incubating the above-described transformant and recovering the human AT III mutant produced by the transformant from the culture.

The present invention further relates to a drug composition for thrombotic disorders which contains the 35 human AT III mutant according to the present invention and pharmaceutically acceptable carriers, a use of the human AT III mutant according to the present invention for the making of a medicament for treating thrombotic disorders, and a method for treating thrombotic disorders which comprises administering a pharmaceutically effective amount of the human AT III mutant according to the present invention to a patient suffering from the thrombotic disorders.

40 Further scope and the applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

45 The present invention will be described hereinafter in detail.

The term "AT III" means human AT III in the following description.

Detailed Description of the Invention

50 1) Isolation of cDNA coding for AT III

Since AT III is mainly synthesized in the liver, a commercially available human liver cDNA library (λ gt 11, available from Clontech) may be used for the isolation of cDNA coding for AT III. Cloning can be effected by a publicly known method. For example, the plaque hybridization method with the use of a 55 synthetic oligonucleotide corresponding to AT III amino acid sequence as a probe [see Sambrook, J. et al., Molecular Cloning, Cold Spring Harbor Laboratory (1989)] may be used therefor.

The clones thus obtained are subcloned into a plasmid such as pUC 18, if required. The nucleotide sequence of cDNA thus obtained can be determined and estimated by the Maxam-Gilbert method [see

Maxam, A.M. and Gilbert, W., Proc. Natl. Acad. Sci. USA, 74, 560 (1977)] or the dideoxy method [Sanger, F., Science, 214, 1205 (1981)]. The nucleotide sequence of the coding region of AT III cDNA thus obtained and the amino acid sequence deduced therefrom are given in SEQ ID. No. 1 in the sequence listing. The amino acid sequence was also described in SEQ ID No. 2 in sequence listing.

2) Method for site-directed mutagenesis

Examples of the method for site-directed mutagenesis include a method of Zoller et al. [see Zoller, M. and Smith, M, Methods in Enzymology, 100, 468 (1983)], the one of Kramer et al. [see Kramer, W. and Fritz, H-J, Methods in Enzymology, 154, 350 (1987)] and the one of Vandeyar et al. [see Vandeyar et al., Gene, 65, 129 (1988)].

In the method of Kramer et al., which is called the gapped duplex method, amber mutants of M13 phage such as M13tv18 and M13tv19 are usable as a vector. A DNA coding for AT III is cloned into these vectors. The single-stranded DNA thus obtained and a double-stranded DNA fragment of M13 free from amber mutation (a vector fragment obtained by cleaving M13mpP with Pvu II) are denatured and subjected to degenerative annealing to thereby give a gapped duplex DNA. Next, this DNA is hybridized with a synthetic oligonucleotide having the mutation to be introduced thereinto. After filling up the gap by treating with DNA polymerase and DNA ligase, it was transfected into *E. coli* mutS strain (BMH71-18 mutS). Then a nonamber phage capable of growing exclusively in supO *E. coli* is selected. Thus a phage having the desired mutation introduced thereinto can be efficiently obtained. In a practical operation, a commercially available kit (Mutan-G, manufactured by Takara Shuzo Co., Ltd.) may be used. On the other hand, the method of Vandeyar et al. is effected as follows. A single-stranded DNA of M13, into which a DNA coding for AT III has been cloned, is hybridized with an oligonucleotide having the mutation to be introduced. By using it as a template, dATP, dGTP, dTTP and 5-methyl-dCTP are used as substrates and treated with T7 DNA polymerase. The double-stranded DNA thus formed is treated with T4 DNA ligase to thereby give a closed-circular double-stranded DNA. Next, this double-stranded DNA is treated with a restriction enzyme MspI and then with exonuclease III. Thus a circular single-stranded DNA exclusively consisting of a strand having the mutation introduced thereinto is obtained. Then it is transfected into an *E. coli* (SDM strain) free from any restriction system specific for methylated DNA. Thus the desired clone can be efficiently obtained. In the case of this method, a commercially available kit may be used in practice (T7-GEN In Vitro Mutagenesis Kit, manufactured by United States Biochemical Corporation). The synthetic oligonucleotide having the mutation to be introduced can be synthesized by the phosphoramidite method with the use of a DNA synthesizer (Model 380 A, manufactured by ABI).

3) Preparation of template for introducing AT III cDNA mutation

A template for introducing mutation is prepared by inserting restriction sites before and after the coding region of the AT III cDNA obtained in the item 1). The restriction enzymes may be selected from among publicly known ones. In the case of the present invention, a Hind III restriction site was inserted immediately before the coding region of the AT III cDNA while a Bgl II restriction site was inserted immediately thereafter.

First, a plasmid containing the AT III cDNA obtained in the item 1) described above is cleaved with EcoR I and thus a fragment of 1.5 kb including the whole AT III coding region is obtained. This fragment is inserted into a linearized product obtained by cleaving the RF (Replicative Form, a double-stranded DNA) of phage M13tv18 with EcoR I.

Among the clones thus obtained, a single-stranded DNA containing the sense strand of AT III is used as a template. In accordance with the method of Kramer et al., two synthetic oligonucleotides containing the restriction sites of Hind III and Bgl II respectively are used as primers and the restriction sites are inserted before and after the coding region of the AT III cDNA.

Subsequently, a fragment containing the AT III cDNA sequence obtained from the clone is inserted into an appropriate plasmid to thereby construct a template for introducing mutation.

In the case of the present invention, a template for introducing mutation can be prepared by inserting the DNA fragment of about 1.5 kb containing the whole AT III coding region, which is obtained by cleaving the above-mentioned clone with Hind III and EcoR I, into the plasmid M13tv19 RF or M13mp19 cleaved with the same enzymes.

Further, the AT III cDNA has a Sac I restriction site (the base part at the 721- to 726-positions in SEQ. ID No. 1) whereby the reactive site can be separated from the heparin binding site. Accordingly, the N-terminal side of AT III obtained by cleaving the above-mentioned clone with Hind III and Sac I, namely, the

DNA fragment containing the heparin binding site is inserted into the plasmid M13tv19 or M13mp19 cleaved with the same enzymes. Thus a template for introducing mutation into the heparin binding site can be prepared.

Regarding the reactive site, a similar operation can be carried out by using EcoR I and Sac I.

4) Introduction of mutation into the desired site

In the amino acid sequence of AT III, an amino acid at a desired position can be mutated into another desired amino acid (hereinafter referred to as the desired amino acid) in accordance with the above-mentioned publicly known methods by using a synthetic oligonucleotide containing a DNA coding for the desired amino acid and an appropriate plasmid described in the item 3) as a template. When Gly at the 392-position in AT III is to be mutated into Pro, for example, the AT1R oligonucleotide given in Table 1 may be used. In order to mutate Ala-Gly at the 391-to 392-positions into Phe-Pro, the AT5R oligonucleotide listed in Table 1 may be used. When a number of amino acids separately located are to be mutated, a number of mutations can be introduced by successively effecting the operations for introducing the mutations one by one.

Typical examples of oligonucleotides employed in the present invention are listed in Tables 1 and 2. Amino acid mutation positions and desired amino acids are listed in Tables 3 and 4. Base codons coding for the desired amino acids are not restricted to those listed in Tables 1 and 2 but any codon may be used therefor so long as it codes for the desired amino acid.

Table 1

Nucleotide sequence of synthetic oligonucleotide for introducing AT III mutation, amino acid to be mutated and position thereof

Oligonucleotide	Nucleotide sequence	Amino acid to be mutated and its position
AT1R	5' GTTTAGCGACCGCGGAGCAATCAC 3'	Gly392 -Pro
AT5R	5' GGGGTTTAGCGACCGCGGAAAAATCACAACAGC 3'	Ala391 -Phe Gly392 -Pro
AT7R	5' TAGCGAACGGCGGACAGGCCACACAGCGGT 3'	Ile390 -Ala Ala391 -Val
AT9R	5' CAGCGGTACTGCCAGCTGCTTC 3'	Ala384 -Gly
AT19R	5' ACGGCCAGCAATGGAAACAGCGGTACT 3'	Val389 -Pro
AT24R	5' AATCACAACAAAGGTACTTGCAG 3'	Ala387 -Phe
AT26R	5' GTTTAGCGAACGGGGAATAATCACAACAGC 3'	Ala391 -Ile Gly392 -Pro
AT27R	5' GTTTAGCGAACGGGACCAATCACAACAG 3'	Ala391 -Gly Gly392 -Pro
AT28R	5' GTTTAGCGAACGGGATATAATCACAACAGC 3'	Ala391 -Tyr Gly392 -Pro
AT29R	5' GTTTAGCGAACGGGCCAATAATCACAACAGC 3'	Ala391 -Trp Gly392 -Pro
AT30R	5' GTTTAGCGAACGGGGAACAATCACAACAG 3'	Ala391 -Val Gly392 -Pro
AT34R	5' TAGCGAACGGCCCAATAGCCACACAGCGGT 3'	Ile390 -Ala Ala391 -Ile
AT35R	5' TAGCGAACGGCCCAAGAGCCACACAGCGGT 3'	Ile390 -Ala Ala391 -Leu
AT38R	5' TAGCGAACGGCCCAAGACCCACACAGCGG 3'	Ile390 -Gly Ala391 -Leu
AT39R	5' GTTTAGCGAACGGGGAACAGCCACACAGCGGTA 3'	Ile390 -Ala Ala391 -Val Gly392 -Pro

The underlined part in the nucleotide sequence represents the sequence corresponding to the amino acid to be mutated.

Table 2

Nucleotide sequence of synthetic oligonucleotide for introducing AT III mutation, amino acid to be mutated and position thereof

Oligonucleotide	Nucleotide sequence	Amino acid to be mutated and its position
AT40R	5' GTTTAGCGAACGGGGGAAAAAGCACACAGCGGTA 3'	Ile390 -Leu Ala391 -Phe Gly392 -Pro
AT46R	5' GTTTAGCGAACGGGGGAGAAATCACAAACAGC 3'	Ala391 -Leu Gly392 -Pro
AT48R	5' GTTTAGCGAACGGGGGATAAGCCACACAGCGGTA 3'	Ile390 -Ala Ala391 -Tyr Gly392 -Pro
AT49R	5' GTTTAGCGAACGGGGGCAAGCCACACAGCGGT 3'	Ile390 -Ala Ala391 -Trp Gly392 -Pro
AT50R	5' GTTTAGCGAACGGGGGCAAGCCACACAGCGGT 3'	Ile390 -Leu Ala391 -Trp Gly392 -Pro
AT2R	5' GAAAGTCACCCCTCTGGGGTTTAGCGAAC 3'	Asn398 -Glu
AT5R	5' TTGAAAGTCACCCCTCTGGGGTTTAGCGAACG 3'	Asn398 -Arg
AT6R	5' TTGAAAGTCACCCCTCTGGGGTTTAGCGAACG 3'	Pro397 -Arg Asn398 -Arg
AT1G	5' CGGCAGTTCAGTTGGGCAAGAAAG 3'	Lys125 -Gln
AT2G	5' GGATTGTGGCGTTTGTAGATCGGGCA 3'	Arg132 -Gln Lys133 -Asn
AT7G	5' GATAGAGTTGGCAGTTTCAG 3'	Arg129 -Gln
AT8G	5' GGTGGCCTCCAGGATCTTCTG 3'	Pro 41 -Leu
AT9G	5' GGGATTTCATGGGAATGGATCGTGGGATTGCTGTGCAGAT '3	Lys 11 -Ile Asp 14 -Ser
AT1F	5' GTTGGCTTTTGTAGATGAGTCG 3'	Arg132 -Gln
AT2F	5' TTTGTTGGCGTTTCGATAGAG 3'	Lys133 -Asn
AT3F	5' TTTGTTGGCTTGTGCATAGAG 3	Lys133 -Gln

The underlined part in the nucleotide sequence represents the sequence corresponding to the amino acid to be mutated.

Table 3

Mutated amino acid in AT III mutant

Amino acid no. Natural AT III	11	14	125	129	132	133	384	390	395	398
	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ile Ala Gly Arg	Ser Leu Asn Pro Asn	
1R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ile Ala Pro Arg	Ser Leu Asn Pro Asn	
5R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ile Phe Pro Arg	Ser Leu Asn Pro Asn	
26R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ile Ile Pro Arg	Ser Leu Asn Pro Asn	
27R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ile Gly Pro Arg	Ser Leu Asn Pro Asn	
28R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ile Tyr Pro Arg	Ser Leu Asn Pro Asn	
29R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ile Trp Pro Arg	Ser Leu Asn Pro Asn	
30R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ile Val Pro Arg	Ser Leu Asn Pro Asn	
46R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ile Leu Pro Arg	Ser Leu Asn Pro Asn	
39R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ala Val Pro Arg	Ser Leu Asn Pro Asn	
40R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Leu Phe Pro Arg	Ser Leu Asn Pro Asn	
48R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ala Tyr Pro Arg	Ser Leu Asn Pro Asn	
49R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ala Trp Pro Arg	Ser Leu Asn Pro Asn	
50R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Leu Trp Pro Arg	Ser Leu Asn Pro Asn	
7R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ala Val Gly Arg	Ser Leu Asn Pro Asn	
34R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ala Ile Gly Arg	Ser Leu Asn Pro Asn	
35R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ala Leu Gly Arg	Ser Leu Asn Pro Asn	
38R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Gly Leu Gly Arg	Ser Leu Asn Pro Asn	
9R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Gly Ser	Thr Ala Val Val Ile Ala Gly Arg	Ser Leu Asn Pro Asn	
19R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Pro Ile Ala Gly Arg	Ser Leu Asn Pro Asn	
24R	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Phe Val Val Ile Ala Gly Arg	Ser Leu Asn Pro Asn	
2R'	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ile Ala Gly Arg	Ser Leu Asn Pro Glu	
5R'	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ile Ala Gly Arg	Ser Leu Asn Pro Arg	
6R'	Lys	--- Asp	--- Lys	--- Arg	--- Arg	--- Lys	--- Ala Ser	Thr Ala Val Val Ile Ala Gly Arg	Ser Leu Asn Arg Arg	

Table 4

Mutated amino acid in AT III mutant

[illegible]

55 5) Combination of mutation in the neighborhood of reactive site and mutation at heparin binding site

As described above, AT III cDNA involves a Sac I restriction site which is located between the reactive site and the heparin binding site. Thus a fragment containing the heparin binding site and another one

containing the reactive site can be obtained by cleaving a plasmid containing the mutated AT III DNA obtained by the method described in the aforementioned item 4) with Hind III and SacI or Sac I and Bgl II. An AT III mutant DNA, in which both of the reactive and heparin binding sites have mutated, can be prepared by treating an AT III DNA having a mutated reactive site and another AT III DNA having a mutated heparin binding site, respectively, with restriction enzymes to thereby give a DNA fragment having a mutated reactive site and another DNA fragment having a mutated heparin binding site and connecting the mutated DNA fragments with an appropriate plasmid. According to this method, any combination of mutations at these sites can be achieved. Any plasmid can be used as the one to which the mutated DNA fragments are connected so long as it is suitable for the expression thereof in a host. For example, pSV2 and pK4K are usable.

In Table 4, a symbol 2G35R means a mutant obtained by combining a 2G-mutated DNA fragment with a 35R-mutated one.

6) AT III mutant recombinant expression vector and transformant thereof

The DNA coding for the AT III mutant obtained by the above-mentioned method is inserted into an appropriate vector and then the vector obtained is transfected into appropriate host cells. Thus a transformant can be obtained. This transformant is incubated by a conventional method and thus an AT III mutant can be produced in a large amount from the culture.

A DNA coding for an AT III mutant is reconnected to a vector suitable for the expression of the AT III mutant at the downstream of the promoter of the vector by a publicly known method with the use of a restriction enzyme and DNA ligase. Thus a recombinant expression vector can be constructed. The vector is not particularly restricted, so long as it can be replicated and amplified in a host. Neither the promoter, nor the terminator is particularly restricted too, so long as they correspond to the host to be used in the expression of the nucleotide sequence coding for the AT III mutant. Thus an appropriate combination thereof may be selected depending on the employed host.

The recombinant expression vector thus obtained is transfected into a host by the competent cell method [see Hanahan, D., J. Mol. Biol., 166, 557 (1983)], the calcium phosphate method [see Wigler, M. et al., Cell, 11, 222(1977)] and so on to thereby form a transformant. As the host, *E. coli*, animal cells, etc. are usable. The transformant thus obtained is incubated in a medium suitable for the host. The incubation may be usually carried out at a temperature of from 20 to 45 °C at a pH value of from 5 to 8 with aeration and stirring, if necessary. The AT III mutant can be separated and purified from the culture by combining publicly known separation and purification methods. Examples of these publicly known methods include salting out, solvent precipitation, dialysis, gel filtration, electrophoresis, ion exchange chromatography, affinity chromatography and reversed phase high performance liquid chromatography. The AT III mutant thus obtained has an elevated antithrombin activity in the absence of heparin and an elevated in vivo antithrombotic action in rat as each compared with natural AT III.

Effects of the Invention

(1) Antithrombin activity

By using a Testzym AT III 2 Kit (manufactured by Daiichi Kagaku Yakuhin), the antithrombin activity of the AT III mutant according to the present invention was measured. Namely, the inhibition activity on thrombin thereof in the absence of heparin was measured by using a synthetic substrate (S-2238) of thrombin. As a control, a plasma derived AT III concentrate (Anthrobin P; manufactured by Hoechst Japan) was employed.

In this measurement, a 50 mM Tris hydrochloride buffer solution (pH 7.5) containing 0.1% of bovine serum albumin and 0.15 M of sodium chloride was used. Specimens of various concentrations were reacted with a given amount of thrombin (originated in bovine) at 37 °C for 5 minutes. After the completion of the reaction, the synthetic substrate S-2238 was added and the amount of p-nitroaniline liberated for 2 minutes was determined based on a change in the absorbance at a wavelength of 405 nm. Thus, the remaining thrombin activity was measured. Under these conditions, the AT III mutant concentration at which 50% of the thrombin activity was inhibited (hereinafter referred to as the IC₅₀) was calculated.

Table 5 shows the IC₅₀ values of mutants. The IC₅₀ of the plasma derived AT III concentrate in the absence of heparin was 13.0×10^{-8} M and that of the natural recombinant AT III was on almost the same level. In contrast, the IC₅₀ values of the AT III mutants of the present invention were clearly lower than them, suggesting that the antithrombin activity in the absence of heparin had been elevated.

Table 5

Antithrombin activity of AT III mutant			
Specimen	Antithrombin activity $IC_{50} \times 10^{-8} (M)$	Specimen	Antithrombin activity $IC_{50} \times 10^{-8} (M)$
AT III concentrate	13.0		
Natural recombinant AT III	14.0		
1R	3.0		
5R	1.7	38R	6.1
26R	3.1	9R	5.8
27R	8.2	19R	8.7
28R	2.8	24R	10.0
29R	1.8	2R'	3.8
30R	2.3	5R'	4.7
46R	5.0	1G1R	3.7
39R	5.6	1G5R	2.9
40R	3.1	2G1R	3.8
48R	5.7	2G5R	2.9
49R	5.6	2G30R	1.6
50R	3.0	2G35R	2.2
7R	2.9	7G5R	1.8
34R	3.5	9G5R	1.7
35R	3.5	127G5R	1.5

(2) Affinity for heparin

The affinities for heparin of the AT III mutants according to the present invention were compared and examined by the high performance liquid chromatography method with the use of Heparin-5PW (7.5 mm × 75 mm; manufactured by Tosoh Corp.). Namely, a 50 mM Tris hydrochloride buffer solution (pH 7.5) was used as a mobile phase and the concentration of sodium chloride was linearly increased from 0 M to 2 M within 30 minutes at a flow rate of 1 ml/min. The detection was effected based on the absorption at a wavelength of 280 nm and the time required for the elution of each specimen was compared.

As Table 6 shows, the main peak fractions of the AT III and the natural recombinant AT III were eluted, respectively, 22.3 minutes and 23.1 minutes after the initiation of the elution, showing no large difference. Compared with the AT III and the natural recombinant AT III, the mutants having a mutation in the neighborhood of the reactive site showed no remarkable difference. On the other hand, the mutants having mutations in the neighborhood of the reactive site and at the heparin binding site showed each a significantly shortened elution time of the main peak fraction. It was thus confirmed that the introduction of a mutation into the heparin binding site would have lowered the affinity for heparin.

Table 6

Affinity for heparin of AT III mutant (elution time from heparin column)			
Specimen	Elution time (min)	Specimen	Elution time (min)
AT III concentrate	22.3		
Natural recombinant AT III	23.1		
5R	21.4	9R	22.5
26R	21.2	19R	23.2
28R	22.5	24R	23.4
29R	21.0	5R'	23.6
30R	20.4	1G1R	14.0
46R	17.4	1G5R	14.3
40R	21.0	2G1R	12.5
48R	21.6	2G5R	12.9
7R	21.9	2G30R	13.0
35R	22.1	2G35R	13.1
38R	21.9	7G5R	12.9
		127G5R	10.2

(3) Antithrombotic action of AT III mutant

By using a plasma derived AT III concentrate (Anthrobin P; manufactured by Hoechst Japan) and a natural recombinant AT III as controls, the antithrombotic actions of the AT III mutants according to the present invention were measured by the following method.

A method reported by Peters et al. [see Peters, R.F. et al., Thrombosis Haemostasis, 65, 268 (1991)] was modified and employed. Namely, a shunt was formed by cannulating Atom Venous Catheter (4Fr, 3.5 cm, manufactured by Atom) filled with a physiological saline into the carotid arteriovein of a male Sprague-Dawley rat (200 - 300 g) under anesthesia. After blocking the blood stream, the artery side of the shunt was provided with a pulse wave pickup (MPP-3, manufactured by Nippon Kodan) and thus changes in the blood stream were monitored with a polygraph recorder during the test period. A calculated amount of a specimen material was diluted with a physiological saline to give a volume of 1 ml and quickly administered once to the rat via the femoral vein. Then the shunt was opened and the blood was allowed to pass. The time required from the point of opening the shunt to the point of the occlusion of the shunt due to the formation of a thrombus was measured and defined as the occlusion time.

Tables 7 and 8 show the results. It was thus proved that the AT III mutants of the present invention had strong antithrombotic actions as compared with the plasma derived AT III concentrate and the natural recombinant AT III.

Table 7

Antithrombotic action of AT III mutant			
Specimen	Dose (mg/kg)	Occlusion time Mean \pm SD (min)	Case no.
Physiological saline		21.4 \pm 2.7	11
AT III concentrate	8	29.1 \pm 8.0	9
	16	36.4 \pm 11.6	8
	32	46.6 \pm 14.3	8
Natural recombinant AT III	16	39.3 \pm 10.5	6
	32	49.0 \pm 13.7	4
5R	8	46.0 \pm 18.6	7
	16	65.7 \pm 21.0	6
30R	4	35.3 \pm 7.1	6
	8	43.6 \pm 4.7	6
	16	52.2 \pm 5.3	6
35R	2	34.7 \pm 5.8	7
	4	39.9 \pm 9.4	7
	8	61.4 \pm 12.6	7
1G5R	4	34.1 \pm 8.7	8
	8	45.2 \pm 10.1	6
	16	69.0 \pm 25.7	6
2G5R	4	45.7 \pm 7.5	7
	8	53.6 \pm 9.3	9
	16	70.6 \pm 11.5	8
2G30R	4	35.5 \pm 5.5	6
	8	45.7 \pm 11.2	6
	16	53.8 \pm 13.7	6
2G35R	2	43.8 \pm 6.6	6
	4	45.2 \pm 5.8	6
	8	62.7 \pm 28.2	6

Table 8

Antithrombotic action of AT III mutant			
Specimen	Dose (mg/kg)	Occlusion time Mean \pm SD (min)	Case no.
1F5R	4	38.3 \pm 6.0	6
	8	41.3 \pm 7.1	6
	16	54.7 \pm 13.1	6
2F5R	4	39.5 \pm 6.1	6
	8	47.8 \pm 9.5	6
	16	59.8 \pm 16.1	6
3F5R	4	38.5 \pm 6.3	6
	8	45.3 \pm 5.2	6
	16	55.7 \pm 4.5	6
7G5R	4	36.5 \pm 5.1	6
	8	39.7 \pm 3.9	6
	16	54.2 \pm 18.3	6
9G5R	2	38.3 \pm 2.7	6
	4	38.5 \pm 3.1	6
	8	49.2 \pm 2.8	6
12G5R	2	36.5 \pm 6.0	6
	4	43.7 \pm 2.7	6
	8	51.2 \pm 6.3	6
127G5R	2	36.0 \pm 7.4	6
	4	46.8 \pm 4.4	6
	8	57.0 \pm 10.9	6

These results suggest that the AT III mutants according to the present invention serve as anticoagulants and suppress the formation of thrombi. Thus there are expected to be useful as preventive and therapeutic agents for thrombotic disorders.

(4) Effect of AT III mutant on experimental model of disseminated intravascular coagulation (DIC)

By using a plasma derived AT III concentrate as a control, the effects of the AT III mutants according to the present invention on an experimental model of disseminated intravascular coagulation (DIC) were examined by the following method. A method reported by Sugishima et al. [see Tadashi Sugishima et al., Rinsho to Kenkyu, 62, 274 (1985)] was modified and employed. Namely, a model was formed by cannulating an Atom Venous Catheter (3Fr, manufactured by Atom) into the jugular vein of a male Sprague-Dawley rat (200 - 300 g) under anesthesia and continuously administering tissue thromboplastin (Thromborel S, manufactured by Behringwerke, AG) for an hour. A test specimen was rapidly administered once via the femoral artery of the rat immediately before starting the administration of tissue thromboplastin. Thirty minutes after the completion of the administration of tissue thromboplastin, the blood was sampled via the descending aorta of the rat and 1/10 volume of 3.8 % sodium citrate was added thereto. After the sampling, 0.5 ml of the blood was immediately taken in a container for an automatic hemocytometer (manufactured by Toa Iyo Denshi K.K.) and platelets were counted with an H.1 System (manufactured by Technicon). The residual blood was centrifuged (3000 rpm, 10 min) to thereby give the plasma. Then fibrinogen contained in the plasma was determined. The content of fibrinogen in the plasma was measured by the thrombin time method (Fibrinogen B-Test Wako, manufactured by Wako Pure Chemical Industries, Ltd.).

Table 9 shows the results. Thus it was found out that the AT III mutants of the present invention exerted strong effects on a decrease in platelet count and the reduction of plasma fibrinogen level in the experimental DIC model induced with tissue thromboplastin as compared with the plasma derived AT III concentrate. Based on these results, the AT III mutants of the present invention are expected as a useful therapeutic agent for DIC.

Table 9

Effect of AT III mutant on experimental DIC model				
Specimen	Dose (mg/kg)	No. of cases	Platelet count ($\times 10^3/\mu\text{l}$) Mean \pm SD	Amount of plasma fibrinogen (g/l) Mean \pm SD
Physiological saline (no tissue thromboplastin administered)		12	952.7 \pm 110.6	1.95 \pm 0.15
Sole administration of tissue thromboplastin		12	424.1 \pm 122.3	0.12 \pm 0.03
AT III concentrate	8	12	527.0 \pm 108.8	0.17 \pm 0.06
	16	11	596.6 \pm 60.9	0.20 \pm 0.07
	32	12	683.7 \pm 128.9	0.77 \pm 0.41
1G5R	4	6	574.7 \pm 54.2	0.36 \pm 0.42
	8	6	729.7 \pm 77.6	0.99 \pm 0.54
2G5R	4	6	618.5 \pm 116.1	0.21 \pm 0.07
	8	6	618.2 \pm 146.3	0.77 \pm 0.28
1F5R	4	6	557.2 \pm 154.4	0.30 \pm 0.34
	8	6	649.5 \pm 112.6	0.64 \pm 0.39
2F5R	4	6	528.8 \pm 89.1	0.24 \pm 0.08
	8	5	659.8 \pm 53.6	0.63 \pm 0.24
3F5R	4	6	487.3 \pm 83.4	0.16 \pm 0.08
	8	6	664.5 \pm 61.5	0.54 \pm 0.37

This AT III mutant can be orally, topically, intravenously, intramuscularly or subcutaneously administered, among which topical or intravenous administration is preferable. The dose may range from 0.1 to 100 mg/kg and preferably from 0.5 to 20 mg/kg, and is determined depending on the body weight of the patient. It is dissolved in from 1 to 50 ml of a physiological saline and used.

It may be formulated into, for example, wettable powders, solutions, tablets, capsules, powders, suppositories and the like. As carriers for formulating these preparations, pharmaceutically acceptable fillers, disintegrating agents, lubricants and dispersion media commonly employed in the art may be used.

Brief Description of the Drawings

- Fig. 1 is a figure showing a process for constructing pKCRNK.
 Fig. 2 is a figure showing a process for constructing pUC19st⁻Ad.
 Fig. 3 is a figure showing a process for constructing pAdPst⁻.
 Fig. 4 is a figure showing a process for constructing pKCRNKAd.
 Fig. 5 is a figure showing a process for constructing pKCR5H3B.
 Fig. 6 is a figure showing a process for constructing pKCR5H3BAAd.
 Fig. 7 is a figure showing a process for constructing pKCRAdEcoB⁻H⁻.
 Fig. 8 is a figure showing a process for constructing pKNK.
 Fig. 9 is a figure showing a process for constructing pK4K.
 Fig. 10 is a figure showing a process for constructing pKCR5RAAd.

Examples

To further illustrate the present invention in detail and concretely, the following Examples will be given, though it is to be understood here that the present invention is never restricted thereto.

Example 1

Cloning of DNA sequence coding for AT III

By the use of a commercially available human liver cDNA library (λ gt 11, available from Clontech) as a starting material, screening was effected by a conventional method with a 32 P-labeled synthetic oligonucleotide as a probe. The sequence of the synthetic oligonucleotide comprised the nucleotide sequence corresponding to the amino acids at the 314- to 322-positions of AT III based on the report by Chandra et al.

As the result of the screening, two clones #2 and #6 were obtained. DNA fragments were collected from each clone by using a restriction enzyme EcoR I and subcloned into M13mp18 to thereby determine the nucleotide sequence. As a result, it was confirmed that the clone #2 contained a fragment of about 1.3 kb corresponding to the sequence of the 33rd amino acid to polyA, while another clone #6 contained a fragment of about 1.1 kb corresponding to the initiation codon to the 348th amino acid. Subsequently, inserts were excised from these clones by using EcoR I and each of the inserts was subcloned into pUC18 cleaved with EcoR I. Thus pUC-H and pUC-L were prepared respectively from the clones #2 and #6.

Next, a DNA fragment of about 3.7 kb (containing a sequence of about 1.0 kb corresponding to pUC18 and the N-terminal side of antithrombin III), which was obtained by cleaving pUC-L with Nco I and Hind III, was connected to another DNA fragment of about 0.5 kb (containing a sequence corresponding to the C-terminal side of antithrombin III) which was obtained by cleaving pUC-H with Nco I and Hind III. Thus a plasmid AT III FLpUC containing all coding regions ranging from the initiation codon to the terminator codon of AT III was obtained. The whole sequence from the initiation codon to the terminator codon of the AT III cDNA contained in this plasmid was represented by SEQ ID No. 1 in the sequence listing.

Example 2

Insertion of restriction site

By the use of the plasmid AT III FLpUC obtained in the above Example 1 as a starting material, a DNA having a Hind III restriction site inserted immediately before the AT III coding sequence and a Bgl II restriction site immediately thereafter was prepared. First, AT III FLpUC was cleaved with EcoR I to thereby give a fragment of about 1.5 kb containing the whole AT III coding region. This fragment was inserted into the above-mentioned one obtained by cleaving RF of M13tv18 with EcoR I to linearize. Among the clones thus obtained, a clone giving the sense strand of AT III as a single-stranded DNA was referred to as tvATR. By using the single-stranded DNA of this tvATR as a template and the two synthetic oligonucleotides given below, each containing the restriction site of each enzyme, as a primer, the restriction sites were introduced in accordance with the method of Kramer et al.

AT5H 25mer:

5' TACATGGCCGAAGCTTCGTAATCAT 3'.

AT3B 29mer:

5' CAAAGAATAAGATCTTATTACTTAACACA 3'.

In the practical operation, a commercially available kit (Mutan G, manufactured by Takara Shuzo Co., Ltd.) was used. Namely, about 0.5 μ g of the single-stranded DNA of tvATR and 0.2 μ g of dsDNA contained in the kit (obtained by cleaving the RF DNA of a phage M13mpP lacking in a Pvu II fragment containing the multiple-cloning site of M13mp18 with Pvu II to linearize) were allowed to stand in 20 mM Tris-HCl pH 8 - 10 mM MgCl₂ - 50 mM NaCl - 1 mM DTT at 100°C for 3 minutes, at 65°C for 10 minutes and at 37°C for 10 minutes to thereby form a gapped duplex. A 1/10 portion of this gapped duplex was collected and mixed with 5 pmol portions of AT5H and AT3B the 5'-end of which had been substituted with phosphate with T4 polynucleotide kinase, and the resulting mixture (3 μ l in total) was allowed to stand at 65°C for 15 minutes and at 37°C for 15 minutes. Next, 25 μ l of a buffer solution contained in the kit [50 mM Tris-HCl pH 8 - 60 mM ammonium acetate - 5 mM MgCl₂ - 5 mM DTT - 1 mM NAD - 0.5 mM each of dNTPs (A, C, G, T)], 60 U of *E. coli* DNA ligase and 1 U of T4 DNA polymerase were added thereto and the resulting mixture was allowed to stand at 25°C for about 2 hours. After adding 3 μ l of 0.2 M EDTA (pH 8) and heating at 65°C for 5 minutes, part of the mixture was collected and transfected into competent cells of an *E. coli* BMH71-18mutS strain prepared by the method of Hanahan [see Hanahan, D., J. Mol. Biol., 166, 557 (1983)]. Plaques obtained by using an *E. coli* MV1184 strain as an indicator were picked and incubated by a conventional method to thereby give an RF DNA. This DNA was cleaved with restriction enzymes Hind III and Bgl II and the nucleotide sequence of a clone having a new restriction site was determined by the

dideoxy method. Thus it was confirmed that the desired mutation had been introduced. The clone thus obtained was referred to as AT5H3B.

A DNA fragment of about 1.5 kb obtained by cleaving this AT5H3B with Hind III and EcoR I was inserted into M13tv19RF which had been subjected to linearize by similarly cleaving with Hind III and EcoR I. The clone thus obtained was referred to as tv19-5H3B. A DNA fragment obtained by cleaving a plasmid pSV2-dhfr [see Lee, F. et al., *Nature*, 294, 228 (1981); Subramani, S. et al., *Mol. Cell. Biol.*, 1, 854 (1981)] with Hind III and Bgl II and eliminating a region coding for mouse dihydrofolate reductase (dhfr) was connected to another DNA fragment obtained by cleaving AT5H3B with Hind III and Bgl II too and containing the whole AT III coding region. Thus a plasmid pSV2-5H3B was obtained. Further, a DNA fragment of about 730 bp obtained by cleaving pSV2-5H3B with Hind III and Sac I and coding for the N-terminal side of AT III was inserted into M13tv19 and M13mp19 which had been subjected to linearize by cleaving with Hind III and Sac I to thereby respectively give tv19-ATN and mp19-ATN.

Example 3

a) Preparation of 1R mutant DNA

A sequence coding for an AT III mutant 1R wherein the 392nd Gly of AT III had been substituted with Pro (Table 3) was obtained by the site-directed mutagenesis method. Namely, in accordance with the method of Kramer et al., the single-stranded DNA of AT5H3B obtained in Example 2 was used as a template and treated with a synthetic oligonucleotide AT1R (Table 1) to thereby give the desired clone 1Rmut. The operation was effected by using a commercially available kit (Mutan G) by the same method as the one described in Example 2.

Twelve plaques thus obtained were picked up and analyzed. As a result, five of these clones were found to be the desired ones. The RF DNA of the obtained clone was cleaved with Hind III and Bgl II and the DNA fragment of about 1.4 kb thus obtained was replaced with a mouse DHFR gene in a plasmid pSV2-dhfr, similar to the procedure employed in Example 2, to thereby construct a plasmid pSV2-1R.

b) Preparation of other DNAs having mutation in the neighborhood of the reactive site

In order to introduce a mutation in the neighborhood of the reactive site other than 1R, the above-mentioned method of Kramer et al. was effected by using tv19-5H3B obtained in Example 2 as a template. Thus mutations of 5R, 26R, 28R, 29R, 30R, 39R, 40R, 46R, 48R, 49R, 50R, 27R, 7R, 34R, 35R, 38R, 9R, 19R, 24R, 2R', 5R' and 6R' were introduced. The amino acid sequence in the neighborhood of the reactive site of each of these AT III mutants is given in Table 3, while the sequences of synthetic oligonucleotides employed for the introduction of the mutations are listed in Tables 1 and 2. Similar to the procedure described in Example 2, a reaction for introducing a mutation was performed in accordance with the manual accompanying the kit and several clones thus formed were collected. Then the nucleotide sequences were determined and thus the clones having the desired mutation introduced therein were obtained. From each clone, a DNA fragment of about 1.4 kb was obtained by using Hind III and Bgl II. In the cases of 5R, 26R, 28R, 30R, 27R, 7R, 19R, 24R, 2R', 5R' and 6R', the obtained fragments were replaced with a mouse DHFR gene in pSV2-dhfr in the same manner as those described in Example 2 and Example 3 a) to thereby respectively give plasmids pSV2-5R, pSV2-26R, pSV2-28R, pSV2-30R, pSV2-27R, pSV2-7R, pSV2-19R, pSV2-24R, pSV2-2R', pSV2-5R' and pSV2-6R'. In the cases of 39R, 40R, 46R, 48R, 49R, 50R, 34R, 35R and 38R, on the other hand, each of the DNA fragments was replaced with a part of an NKAF gene in a plasmid pK4K which will be described hereinbelow to thereby respectively give plasmids pK4K-39R, pK4K-40R, pK4K-46R, pK4K-48R, pK4K-49R, pK4K-50R, pK4K-34R, pK4K-35R and pK4K-38R. In the cases of 29R and 9R, DNA fragments of about 1.4 kb were isolated again from plasmids pSV2-29R and pSV2-9R by using Hind III and Bgl II and plasmids pK4K-29R and pK4K-9R were constructed by the same method as those described above.

Example 4

Preparation of heparin binding site-mutated DNA

Among mutations at the heparin binding site, the mutations of 1G, 2G and 8G were introduced in accordance with the method of Kramer et al. by using tv19-5H3B obtained in Example 2 as a template. The sequences of synthetic oligonucleotides employed therein are given in Table 2. The clones having the

desired mutation introduced thereinto were referred to as 1Gmut, 2Gmut and 8Gmut respectively. From these clones, DNA fragments of about 1.4 kb were excised by using Hind III and Bgl II and treated by the same method as the one employed in the cases of the mutations at the reactive site. Thus plasmids pSV2-1G, pSV2-2G and pSV2-8G were obtained. Further, a DNA fragment of about 730 bp obtained by cleaving pSV2-1G with Hind III and Sac I was inserted into M13lv19 cleaved with the same enzymes to thereby give tv19-1GN.

The mutations of 1F, 2F, 3F and 7G were introduced in the same manner by using tv19-ATN obtained in Example 2 as a template. The M13 clones having the desired mutation introduced thereinto were referred to as 1Fmut, 2Fmut, 3Fmut and 7Gmut, respectively.

The mutation of 9G was introduced in accordance with the method of Vandeyar et al. with the use of mp19-ATN as a template. The practical operation was performed in accordance with the manual accompanying a kit (T7-GEN In Vitro Mutagenesis System available from USB). First, 1 µg of mp19-ATN single-stranded DNA and 2 pmol of a synthetic oligonucleotide AT9G, the 5'-end of which had been substituted with phosphate with T4 polynucleotide kinase, were heated at 65 °C in 40 mM Tris-HCl pH 7.5 - 20 mM MgCl₂ - 50 mM NaCl for 5 minutes and then slowly cooled to room temperature. To this reaction mixture (10 µl) were added 2 µl of 10 X Synthesis mix (100 mM Tris-HCl pH 7.5 - 20 mM DTT - 5 mM dATP - 5 mM dGTP - 5 mM dTTP - 5 mM 5-methyl-dCTP - 10 mM ATP), 2.5 U of T7 DNA polymerase and 5 U of T4 DNA ligase to thereby give a final volume of 20 µl, followed by allowing to stand at 37 °C for 1 hour. Thus an RF DNA, in which the strand having a mutation introduced thereinto had been exclusively methylated, was synthesized. After inactivating the enzyme by heating the reaction mixture at 70 °C for 10 minutes, 5 U portions of restriction enzymes Msp I and Hha I were added and allowed to react at 37 °C for 45 minutes. Thus one of the DNA strands of the double-stranded DNA used as a template which had not been methylated was exclusively nicked with Msp I and the template single-stranded DNA which had not been replicated into the double-stranded one was cleaved with Hha I.

Subsequently, 50 U of exonuclease III was added to the reaction mixture and allowed to react at 37 °C for 45 minutes. Then only the nicked template strand was digested and, as a result, the DNA strand having mutation introduced thereinto was concentrated. After ceasing the reaction by heating at 70 °C for 10 minutes, the reaction mixture was transfected into an *E. coli* SDM strain (mcrAB) free from any restriction system specific for methylated DNA by an ordinary method. Several plaques thus obtained were picked up and DNAs were obtained. Then the nucleotide sequences thereof were determined and thus a clone having the desired mutation introduced thereinto was selected. From the clone thus obtained, a DNA fragment of about 730 bp was isolated by using Hind III and Sac I and inserted into pSV2-5H3B which had been cleaved with the same enzymes to thereby eliminate fragments of the same size. Thus pSV2-9G was obtained.

The 12G mutant was obtained by further introducing a mutation by using a synthetic oligonucleotide AT2G (Table 2) with the use of a DNA having the mutation of 1G introduced thereinto as a template. Namely, it was obtained in accordance with the method of Kramer et al. by using tv19-1GN as a template. After confirming that the desired mutation had been introduced, the obtained clone was referred to as 12Gmut.

The 127G mutant was obtained in accordance with the above-mentioned method of Vandeyar et al. by using a single-stranded DNA of 12Gmut as a template and treating with a synthetic oligonucleotide AT7G. After confirming that the desired mutation had been introduced, the obtained clone was referred to as 127Gmut.

Example 5

Preparation of DNA having mutations both in the neighborhood of the reactive site and at the heparin binding site

a) Preparation of 1G5R mutant DNA

A DNA of the 1G5R mutant having a combination of a mutation 1G at the heparin binding site with another mutation 5R in the neighborhood of the reactive site was constructed in the following manner.

The RF DNA of 1Gmut obtained in Example 4 was cleaved with Hind III and Sac I and thus a DNA fragment of about 730 bp having a mutation at the heparin binding site was prepared. The pSV2-5R obtained in Example 3 was cleaved with Sac I and Bgl II and thus a DNA fragment of about 670 bp having a mutation in the neighborhood of the reactive site was prepared. These DNA fragments were combined together and inserted into pSV2-dhfr from which a mouse DHFR gene had been eliminated by using Hind III

and Bgl II. Thus pSV2-1G5R was constructed. Further, this pSV2-1G5R was cleaved with Hind III and Bgl II and a DNA fragment of about 1.4 kb thus formed was inserted into a plasmid which was obtained by eliminating a part of a NKAF gene in a plasmid pK4K as will be described hereinafter by cleaving the plasmid pK4K with Hind III and BamH I. Thus pK4K-1G5R was constructed. The preparation of these DNA fragments having mutation and the construction of pSV2-1G5R and pK4K-1G5R by combining these mutated DNA fragments were performed in accordance with publicly known methods. *E. coli* HB101-pK4K-1G5R containing the plasmid pK4K-1G5R has been deposited with Fermentation Research Institute of Agency of Industrial Science and Technology of the Ministry of International Trade and Industry under the accession number of FERM BP-3806, on March 26, 1992.

b) Preparation of 2G5R mutant DNA

A DNA of the 2G5R mutant having a combination of a mutation 2G at the heparin binding site with another mutation 5R in the neighborhood of the reactive site was constructed in the following manner.

The RF DNA of 2Gmut obtained in Example 4 was cleaved with Hind III and Sac I and thus a DNA fragment of about 730 bp having a mutation at the heparin binding site was prepared. The pSV2-5R obtained in Example 3 was cleaved with Sac I and Bgl II and thus a DNA fragment of about 670 bp having a mutation in the neighborhood of the reactive site was prepared. These DNA fragments were combined together and inserted into pSV2-dhfr from which a mouse DHFR gene had been eliminated by using Hind III and Bgl II. Thus pSV2-2G5R was constructed. Further, this pSV2-2G5R was cleaved with Hind III and Bgl II and a DNA fragment of about 1.4 kb thus formed was inserted into a plasmid which was obtained by eliminating a part of a NKAF gene in a plasmid pK4K as will be described hereinafter by cleaving the plasmid pK4K with Hind III and BamH I. Thus pK4K-2G5R was constructed. *E. coli* HB101-pK4K-2G5R containing the plasmid pK4K-2G5R has been deposited with Fermentation Research Institute of Agency of Industrial Science and Technology of the Ministry of International Trade and Industry under accession number of FERM BP-3807, on March 26, 1992.

c) Preparation of other both site-mutated DNAs

The DNAs each having a mutation at the corresponding site obtained in Examples 3 and 4 were employed. As a DNA fragment having a mutation at the heparin binding site, DNA fragments of about 730 bp obtained by cleaving pSV2-1G, pSV2-2G, pSV2-9G, 1Fmut, 2Fmut, 3Fmut, 7Gmut, 12Gmut and 127Gmut each with Hind III and Sac I were prepared. Separately, as a DNA fragment having a mutation at the reactive site, DNA fragments of about 670 bp were obtained by cleaving pSV2-1R, pSV2-5R (or pSV2-1G5R) and pSV2-30R each with Sac I and Bgl II. Further, pK4K-35R was cleaved with Sac I and Xho II to thereby give a DNA fragment of about 670 bp (In a DNA prepared by inserting an AT III mutant gene with a Hind III-Bgl II fragment into a plasmid wherein a part of an NKAF gene had been eliminated from pK4K by cleaving with Hind III and BamH I, the Bgl II-cleaved end is connected to the BamH I-cleaved end. Thus it is impossible to cleave this DNA again with Bgl II. However, this site can be cleaved with Xho II.). These DNA fragments were combined together and then inserted into a plasmid wherein a part of the NKAF gene had been eliminated from pK4K by cleaving with Hind III and BamH I. Thus pK4K-1G30R, pK4K-1G35R, pK4K-2G30R, pK4K-2G35R, pK4K-1F5R, pK4K-2F5R, pK4K-3F5R, pK4K-7G5R, pK4K-7G30R, pK4K-7G35R, pK4K-9G5R, pK4K-9G30R, pK4K-9G35R, pK4K-12G5R, pK4K-12G30R, pK4K-12G35R, pK4K-127G5R, pK4K-127G30R and pK4K-127G35R were constructed. Furthermore, pSV2-1G1R and pSV2-2G1R were constructed in a similar manner by using pSV2-dhfr from which a mouse DHFR gene had been eliminated with the use of Hind III and Bgl II.

Example 6

Construction of expression vector for animal cells

a) Construction of natural recombinant AT III and 1R expression vector

A plasmid pNK8308 (disclosed in European Patent Publication-A3 No. 357067) containing a cDNA coding for recombinant natural killer cell activating factor (NKAF) was digested with Bgl II and BamH I and electrophoresed on an agarose gel. Thus an NKAF cDNA fragment of about 0.75 kb was isolated. A plasmid pPCR [see O Hare, K. et al., Proc. Natl. Acad. Sci. USA, 78, 1527 (1981)] was digested with BamH I and dephosphorylated with alkaline phosphatase. The vector DNA thus obtained was connected (ligated) to the

NKAF cDNA fragment by adding T4 DNA ligase to thereby give pKCRNK (Fig. 1).

A plasmid pUC19 was digested with Pst I, then treated with T4 DNA polymerase by a conventional method to thereby blunt (to thereby be blunt-ended) both of the 3'- and 5'-ends and then ligated, thus giving pUC19Pst⁻. Subsequently, this pUC19Pst⁻ was digested with BamH I and dephosphorylated with alkaline phosphatase. The vector DNA thus obtained was ligated with a DNA fragment of about 2.4 kb [containing adenovirus promoter, mouse dihydrofolate reductase (DHFR) gene and SV40 polyA signal], which had been isolated by digesting a plasmid pAdD26SV(A) (no.3) [see Kaufmann, R. and Sharp, P., Mol. Cell. Biol., 2, 1304 (1982)] with BamH I and electrophoresing on an agarose gel, to thereby give pUC19Pst⁻ Ad (Fig. 2). Further, this pUC19Pst⁻ Ad was digested with Pst I and blunt-ended with T4 DNA polymerase and then ligated to thereby give pUC19Pst⁻ AsPst⁻. Then a DNA fragment of about 2.9 kb containing a tetracycline-resistant gene, which had been isolated by digesting pAdD26SV(A) (no. 3) with BamH I, dephosphorylating and electrophoresing on an agarose gel, was ligated with another DNA fragment of about 2.4 kb containing adenovirus promoter, mouse DHFR gene and SV40 polyA signal, which had been isolated by digesting pUC19Pst⁻ AdPst⁻ with BamH I and electrophoresing on an agarose gel, to thereby give pAdPst⁻ (Fig. 3). Then the pAdPst⁻ was digested with EcoR I and blunt-ended by treating with a DNA polymerase I Klenow fragment. Subsequently, it was digested with Pst I and blunt-ended with T4 DNA polymerase. Then Aat II linker was added thereto and ligated therewith and the obtained product was digested with Aat II and electrophoresed on an agarose gel. Thus a DNA fragment of about 2.7 kb containing adenovirus promoter, mouse DHFR gene and SV40 polyA signal was obtained. This DNA fragment was ligated with a DNA obtained by digesting pKCRNK with Aat II and dephosphorylating to thereby give pKCRNKAd (Fig. 4).

The plasmid pSV2-5H3B obtained in Example 2 was digested with Hind III and Bgl II and a DNA fragment of about 1.4 kb containing AT III cDNA was isolated. This fragment was ligated with a vector DNA obtained by digesting a plasmid pIC19R [see Marsh, J.L. et. al., Gene, 32, 481 (1984)] with Hind III and Bgl II to thereby give pIC19R5H3B. Next, this pIC19R5H3B was digested with BamH I and Bgl II and a DNA fragment of about 1.4 kb containing 5H3B cDNA was isolated. This DNA fragment was ligated with a vector DNA obtained by digesting pKCR with BamH I and dephosphorylating to thereby give pKCR5H3B (Fig. 5).

pKCRNKAd was digested with Aat II and a DNA fragment of about 2.7 kb containing adenovirus promoter, mouse DHFR gene and SV40 polyA signal was isolated. This DNA fragment was ligated with a vector DNA obtained by digesting pKCR5H3B with Aat II and dephosphorylating to thereby give pKCR5H3BAd (Fig. 6). The pKCR5H3BAd was used in order to express a natural recombinant AT III in animal cells as will be described in Example 7.

Similarly, by the use of pSV2-1R obtained in Example 3 a) as the starting material, pKCR1RAd was obtained. The pKCR1RAd was used in order to express a mutant 1R in animal cells as will be described in Example 7.

b) Construction of expression vectors of various mutants in animal cells

pKCR5H3BAd was digested with EcoR I and then self-ligated. Thus pKCRAdEco wherein SV40 promoter, a part of the NKAF gene and a part of rabbit β -globin gene had been eliminated was selected. The pKCRAdEco was digested with BamH I, blunt-ended with a DNA polymerase I Klenow fragment and then ligated to thereby give pKCRAdEcoB⁻. Subsequently, the pKCRAdEcoB⁻ was digested with Hind III, blunt-ended with a DNA polymerase I Klenow fragment and then ligated to thereby give pKCRAdEcoB⁻H⁻ (Fig. 7).

pKCRNKAd was digested with Hind III and BamH I and a DNA fragment of about 0.4 kb containing a part of the NKAF gene was isolated. Then it was ligated with a vector DNA obtained by digesting pIC19R with Hind III and BamH I to thereby give pIC19RNKK. The pIC19RNKK was digested with Bgl II and BamH I and a DNA fragment of 0.4 kb containing a part of the NKAF gene was isolated. This DNA fragment was ligated with a vector DNA obtained by digesting pKCR with BamH I and dephosphorylating to thereby give pKNK (Fig. 8).

pKNK was partially digested with EcoR I and a DNA fragment of about 1.5 kb containing SV40 promoter, a part of NKAF gene and a part of rabbit β -globin gene was isolated. Then this DNA fragment was ligated with a vector DNA obtained by digesting pKCRAdEcoB⁻H⁻ with EcoR I and dephosphorylating to thereby give pK4K (Fig. 9).

As Fig. 9 shows, pK4K contains the promoter of an early gene of SV40, the replication initiation region of SV40, a part of the NKAF gene, a part of the rabbit β -globin gene (splicing and polyA signal), the polyA signal of the early gene of SV40, the major late gene promoter and the 5' splice signal of type II adenovirus, rabbit immunoglobulin 3' splice signal, mouse DHFR gene, the polyA signal of the early gene of SV40, the

replication initiation region of pBR322 and a β -lactamase gene originating in pBR322 (Amp^r) and the dhfr was connected on the downstream side of the major late gene promoter of adenovirus and a part of the NKAF gene was connected on the downstream side of the promoter of the early gene of SV40.

An expression vector in animal cells can be constructed by inserting an AT III mutant gene into a site remaining after excising a part of the NKAF gene of pK4K with Hind III and BamH I. In practice, expression vectors of the mutants 1G5R and 2G5R were prepared by using pSV2-1G5R and pSV2-2G5R respectively and pK4K by the above-mentioned method as shown in Example 5 a) and b). These vectors were referred to as pK4K-1G5R and pK4K-2G5R. As described in Example 3 b) and Example 5 c), expression vectors of other mutants were similarly constructed by using pK4K.

c) Construction of expression vectors of mutants 5R and 7R

The plasmid pSV2-5R obtained in Example 3 b) was digested with Hind III and Bgl II and thus a DNA fragment of about 1.4 kb containing a 5R gene was isolated. This DNA fragment was ligated with a vector DNA obtained by digesting pKNK with Hind III and BamH I to thereby eliminate a part of the NKAF gene, thus giving pKNK5R. The pKNK5R was digested with EcoR I and a DNA fragment of about 1.5 kb containing the promoter of the early gene of SV40, a 5R gene and a part of the rabbit β -globin gene was isolated. This DNA fragment was ligated with a vector DNA obtained by digesting pKCRAdEcoB⁺H⁻ with EcoR I and dephosphorylating to thereby give pKCR5RAd (Fig. 10). Similarly, pKCR7RAd was obtained by using pSV2-7R obtained in Example 3 b).

Example 7

Expression of AT III mutant by animal cells

a) Expression by CHO cell

CHO cells [dhfr-deficient strain, see Urlaub, G. and Chasin, L.A., Proc. Natl. Acad. Sci. USA, 77, 4216 (1980)] were inoculated in an incubation flask at a ratio of 7×10^5 cells/5 ml/the flask of 25 cm². On the next day, 3 μ g of the plasmid pKCR1RAd obtained in Example 6 a) was transfected by the calcium phosphate method with the use of a CellPfect (a kit manufactured by Pharmacia). As a medium, one obtained by adding fetal calf serum to a 1 : 1 mixture (a DF medium) of Ham F12 medium with Dulbecco's modified Eagle medium in such a manner that the obtained medium contained 10% of the fetal calf serum, was used. After 3 days, the cells were trypsinized and diluted with a selection medium (DF medium free from hypoxanthine and thymidine + 10% dialyzed fetal calf serum). Then 1 ml portions of the cells contained in one incubation flask (25 cm²) were pipetted into each of wells of four 24-well plates for incubation and the incubation was continued in the selection medium while replacing the medium with a fresh one at intervals of 3 to 4 days. Cells surviving under these conditions were those transformed by the mouse DHFR gene. After approximately 2 weeks, the colonies thus formed were dispersed by trypsinizing in wells and a fresh medium was added, followed by incubating for additional 3 to 4 days. Then the culture broth was exchanged and the amount of 1R contained in the culture supernatant was determined by the EIA method on the next day. Each clone showing an expression yield of about several ten ng/ml/day or more was transinoculated into a selection medium containing 50 nM of methotrexate (MTX) and incubated for 2 to 3 weeks. Further, the MTX concentration was successively elevated to 100 nM, 400 nM and 1000 nM and the incubation was continued in the same manner. Among clones growing at the MTX concentration of 1000 nM, those showing high expression yields were cloned by the limiting dilution method with the use of a 96-well plate. In the state of confluent growth, a clone 110-6, which was a typical example of those thus obtained, secreted about 10 μ g/ml/day of 1R into the culture supernatant at 0.3 ml of the medium/cm². Similarly, CHO cells capable of expressing a natural recombinant AT III were obtained by using pKCR5H3BAd obtained in Example 6 a).

b) Expression of various mutants by BHK cell

i) Use of pSV2 vectors

The plasmids shown in Examples 3 and 5, which were constructed by replacing the mouse DHFR gene in a plasmid pSV2-dhfr by an AT III mutant DNA, can be used for expressing various mutants by transfecting into animal cells together with pSV2-dhfr (cotransfection).

BHK cells [tk⁻ts13 strain, see Waechter, D.E. and Baserga, R., Proc. Natl. Acad. Sci. USA, 79, 1106 (1982)] were inoculated in an incubation flask at a ratio of 5×10^5 cells/5 ml/the flask of 25 cm². On the next day, 7 µg of a plasmid pSV2-28R having a gene of a mutant 28R shown in Example 3 b) introduced thereinto was transfected into the BHK cells together with 3.5 µg of pSV2-dhfr by the calcium phosphate method with the use of CellPfect. As a medium, one obtained by adding fetal calf serum to Dulbecco's modified Eagle medium in such a manner that the obtained medium contained 5% of the fetal calf serum, was used. After 3 days, the cells were trypsinized and subcultured into a 75 cm² incubation flask with a medium containing 200 nM of MTX. After incubating for 10 days while replacing the medium with a fresh one at intervals of 2 to 3 days, the cells were subcultured into a 175 cm² incubation flask with a medium containing 1000 nM of MTX. After incubating for additional 10 days while replacing the medium with a fresh one at intervals of 2 to 3 days, a cell strain showing a high expression yield was cloned by the limiting dilution method with the use of a 96-well plate. A clone #4 thus obtained secreted about 0.7 µg/ml/day of 28R into the culture supernatant at 0.3 ml of the medium/cm² in a state of confluent growth. Regarding the plasmids containing other mutant DNAs which were constructed with pSV2 and described in Examples 3 and 5, expression cells could be obtained by the same method as the one described above.

ii) Use of other vectors

BHK cells (tk⁻ts13 strain) were inoculated in an incubation flask at a ratio of 3×10^5 cells/5 ml/the flask of 25 cm². On the next day, 3 µg of a plasmid pK4K-2G5R having a gene of a mutant 2G5R obtained in Example 5 b) introduced thereinto was transfected into the BHK cells by the calcium phosphate method with the use of CellPfect. As a medium, one obtained by adding fetal calf serum to Dulbecco's modified Eagle medium in such a manner that the obtained medium contained 5% of the fetal calf serum, was used. After 2 days, the cells were trypsinized and diluted with a medium containing 250 nM of MTX. The cells in one 25 cm² incubation flask were pipetted into wells of twelve 24-well plates for incubation. Then the incubation was continued while replacing the medium with a fresh one at intervals of 3 to 4 days. After 12 days, the colonies thus formed were dispersed by trypsinizing in the wells and the medium was added. After incubating for additional 6 days, the culture broth was exchanged. On the next day, the amount of each mutant contained in the culture supernatant was measured by the EIA method and a cell strain showing a high expression yield was cloned. A clone 6-5 thus obtained secreted about 16 µg/ml/day of 2G5R into the culture supernatant at 0.3 ml of the medium/cm² in a state of confluent growth.

Regarding pKCR1RAd, pKCR5RAd and pKCR7RAd described in Example 6 and the plasmids containing other mutant DNAs described in Examples 3 and 5, which were constructed by using pK4K, expression cells were obtained in a similar manner. Further, cells capable of expressing the natural recombinant AT III could be obtained by the same method with the use of pKCR5H3BAd shown in Example 6.

Some of these expression cells were transinoculated into a medium containing 1000 nM of MTX and further incubated. Some of clones incubated in the medium containing 1000 nM of MTX, which showed high expression yields, were cloned by the limiting dilution method with the use of a 96-well plate.

The expression yields of typical examples of the clones thus obtained were shown in Table 10.

Table 10

Expression of AT III mutant by BHK cell			
Mutant	Clone	Amount of secretion into medium ($\mu\text{g/ml}$)	MTX concn. (nM)
natural recombinant AT III	F242	15-20	1000
1R	5-41	25-30	1000
5R	D153	13-15	1000
7R	3-153	20-25	1000
1G5R	11-1	10	1000
6R'	5-21	15	1000
30R	6-18	19	1000
2G5R	6-5	16	250
25R	4-2	20	250
35R	42-5	22	250
29R	22-8	17	250
2G30R	16	19	250
7G5R	1	12	250

The amount of secretion into the medium was expressed in the mutant concentration 24 hours after replacing the medium in a state of confluent growth of cells (the amount of medium was 0.3 ml/cm²).

Example 8

Incubation of mutant expression cells and purification of mutant

The AT III mutant expression cells obtained in Example 7 were incubated in a roller bottle (1750 cm²). As a medium, Dulbecco's modified Eagle medium containing 5% of fetal calf serum and MTX (final concentration being 250 nM or 1000 nM) was used. The cells were inoculated into 300 ml of the medium and incubated at 37 °C. From 3 to 4 days after the initiation of the incubation, the medium was replaced by the same amount of a fresh one everyday and the culture supernatants were combined.

The AT III mutants were purified by affinity chromatography with the use of an antibody column wherein anti AT III monoclonal antibody was bound to a support. Namely, the above-mentioned culture supernatant was charged into an antibody column which had been equilibrated with 50 mM Tris-HCl buffer pH 7.5 - 0.5 M NaCl. After washing with the same buffer, it was eluted with 0.2 M glycine-HCl buffer (pH 2.5). The eluted fractions were immediately neutralized with 1/2 times by volume as much 1 M Tris-HCl (pH 8.0). The fractions thus obtained were dialyzed against Dulbecco's PBS (-), ultrafiltrated and then used in the subsequent test. In the cases of some mutants, the eluted fractions from the antibody column was ultrafiltrated, charged into Sepharacryl S-200 and eluted with Dulbecco's PBS (-) (gel-filtration). The active fraction thus obtained was concentrated and then used in the subsequent test.

During the process of incubation and purification, each AT III mutant was determined by the EIA method with the use of anti AT III antibody.

The natural recombinant AT III employed as a control was also incubated and purified by the same method.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: Eisai Co., Ltd.

(B) STREET: 6-10, Koishikawa 4-chome, Bunkyo-ku

(C) CITY: Tokyo

(E) COUNTRY: Japan

(F) POSTAL CODE (ZIP): 112

(ii) TITLE OF INVENTION: HUMAN ANTITHROMBIN III MUTANTS

(iii) NUMBER OF SEQUENCES: 2

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: JP 90488/92

(B) FILING DATE: 10-Apr-1992

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: JP 31855/93

(B) FILING DATE: 22-Feb-1993

(2) INFORMATION FOR SEQ ID NO: 1:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1395 base pairs
 (B) TYPE: nucleic acid
 10 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens
 20

(ix) FEATURE:
 (A) NAME/KEY: CDS
 25 (B) LOCATION: 1..1395

(ix) FEATURE:
 (A) NAME/KEY: sig_ peptide
 30 (B) LOCATION: 1..96

(ix) FEATURE:
 35 (A) NAME/KEY: mat_ peptide
 (B) LOCATION: 97..1395

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

45 ATG TAT TCC AAT GTG ATA GGA ACT GTA ACC TCT GGA AAA AGG AAG GTT 48
 Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20

50

55

EP 0 568 833 A1

	TAT CTT TTG TCC TTG CTG CTC ATT GGC TTC TGG GAC TGC GTG ACC TGT	96
	Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys	
5	-15 -10 -5	
	CAC GGG AGC CCT GTG GAC ATC TGC ACA GCC AAG CCG CGG GAC ATT CCC	144
	His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro	
10	1 5 10 15	
	ATG AAT CCC ATG TGC ATT TAC CGC TCC CCG GAG AAG AAG GCA ACT GAG	192
	Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu	
15	20 25 30	
	GAT GAG GGC TCA GAA CAA AAG ATC CCG GAG GCC ACC AAC CGG CGT GTC	240
	Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val	
20	35 40 45	
	TGG GAA CTG TCC AAG GCC AAT TCC CGC TTT GCT ACC ACT TTC TAT CAG	288
	Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln	
25	50 55 60	
	CAC CTG GCA GAT TCC AAG AAT GAC AAT GAT AAC ATT TTC CTG TCA CCC	336
	His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro	
30	65 70 75 80	
	CTG AGT ATC TCC ACG GCT TTT GCT ATG ACC AAG CTG GGT GCC TGT AAT	384
	Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn	
35	85 90 95	
	GAC ACC CTC CAG CAA CTG ATG GAG GTA TTT AAG TTT GAC ACC ATA TCT	432
	Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser	
40	100 105 110	
	GAG AAA ACA TCT GAT CAG ATC CAC TTC TTC TTT GCC AAA CTG AAC TGC	480
	Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys	
45	115 120 125	
	CGA CTC TAT CGA AAA GCC AAC AAA TCC TCC AAG TTA GTA TCA GCC AAT	528
	Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn	
50	130 135 140	
55		

EP 0 568 833 A1

	CGC CTT TTT GGA GAC AAA TCC CTT ACC TTC AAT GAG ACC TAC CAG GAC	576
5	Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp 145 150 155 160	
	ATC AGT GAG TTG GTA TAT GGA GCC AAG CTC CAG CCC CTG GAC TTC AAG	624
10	Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys 165 170 175	
	GAA AAT GCA GAG CAA TCC AGA GCG GCC ATC AAC AAA TGG GTG TCC AAT	672
	Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn 180 185 190	
15	AAG ACC GAA GGC CGA ATC ACC GAT GTC ATT CCC TCG GAA GCC ATC AAT	720
	Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn 195 200 205	
20	GAG CTC ACT GTT CTG GTG CTG GTT AAC ACC ATT TAC TTC AAG GGC CTG	768
	Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu 210 215 220	
25	TGG AAG TCA AAG TTC AGC CCT GAG AAC ACA AGG AAG GAA CTG TTC TAC	816
	Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr 225 230 235 240	
30	AAG GCT GAT GGA GAG TCG TGT TCA GCA TCT ATG ATG TAC CAG GAA GGC	864
	Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly 245 250 255	
35	AAG TTC CGT TAT CGG CGC GTG GCT GAA GGC ACC CAG GTG CTT GAG TTG	912
	Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu 260 265 270	
40	CCC TTC AAA GGT GAT GAC ATC ACC ATG GTC CTC ATC TTG CCC AAG CCT	960
	Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro 275 280 285	
45	GAG AAG AGC CTG GCC AAG GTT GAG AAG GAA CTC ACC CCA GAA GTG CTG	1008
	Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu 290 295 300	

EP 0 568 833 A1

	CAG GAG TGG CTG GAT GAA TTG GAG GAG ATG ATG CTG GTG GTC CAC ATG	1056
	Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met	
5	305 310 315 320	
	CCC CGC TTC CGC ATT GAG GAC GGC TTC AGT TTG AAG GAG CAG CTG CAA	1104
	Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln	
10	325 330 335	
	GAC ATG GGC CTT GTC GAT CTG TTC AGC CCT GAA AAG TCC AAA CTC CCA	1152
	Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro	
	340 345 350	
15	GGT ATT GTT GCA GAA GGC CGA GAT GAC CTC TAT GTC TCA GAT GCA TTC	1200
	Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe	
	355 360 365	
20	CAT AAG GCA TTT CTT GAG GTA AAC GAA GAA GGC AGT GAA GCA GCT GCA	1248
	His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala	
	370 375 380	
25	AGT ACC GCT GTT GTG ATT GCT GGC CGT TCG CTA AAC CCC AAC AGG GTG	1296
	Ser Thr Ala Val Val Ile Ala Gly Arg Ser Leu Asn Pro Asn Arg Val	
	385 390 395 400	
30	ACT TTC AAG GCC AAC AGG CCT TTC CTG GTT TTT ATA AGA GAA GTT CCT	1344
	Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro	
	405 410 415	
	CTG AAC ACT ATT ATC TTC ATG GGC AGA GTA GCC AAC CCT TGT GTT AAG	1392
35	Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys	
	420 425 430	
	TAA	1395

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 464 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30
 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45
 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60
 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80
 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95
 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
 115 120 125

EP 0 568 833 A1

	Arg	Leu	Tyr	Arg	Lys	Ala	Asn	Lys	Ser	Ser	Lys	Leu	Val	Ser	Ala	Asn
	130						135					140				
5	Arg	Leu	Phe	Gly	Asp	Lys	Ser	Leu	Thr	Phe	Asn	Glu	Thr	Tyr	Gln	Asp
	145					150					155				160	
	Ile	Ser	Glu	Leu	Val	Tyr	Gly	Ala	Lys	Leu	Gln	Pro	Leu	Asp	Phe	Lys
					165					170					175	
10	Glu	Asn	Ala	Glu	Gln	Ser	Arg	Ala	Ala	Ile	Asn	Lys	Trp	Val	Ser	Asn
					180					185					190	
	Lys	Thr	Glu	Gly	Arg	Ile	Thr	Asp	Val	Ile	Pro	Ser	Glu	Ala	Ile	Asn
15					195				200						205	
	Glu	Leu	Thr	Val	Leu	Val	Leu	Val	Asn	Thr	Ile	Tyr	Phe	Lys	Gly	Leu
	210						215							220		
20	Trp	Lys	Ser	Lys	Phe	Ser	Pro	Glu	Asn	Thr	Arg	Lys	Glu	Leu	Phe	Tyr
	225					230					235				240	
	Lys	Ala	Asp	Gly	Glu	Ser	Cys	Ser	Ala	Ser	Met	Met	Tyr	Gln	Glu	Gly
					245					250					255	
25	Lys	Phe	Arg	Tyr	Arg	Arg	Val	Ala	Glu	Gly	Thr	Gln	Val	Leu	Glu	Leu
					260					265					270	
	Pro	Phe	Lys	Gly	Asp	Asp	Ile	Thr	Met	Val	Leu	Ile	Leu	Pro	Lys	Pro
30					275					280					285	
	Glu	Lys	Ser	Leu	Ala	Lys	Val	Glu	Lys	Glu	Leu	Thr	Pro	Glu	Val	Leu
	290						295							300		
35	Gln	Glu	Trp	Leu	Asp	Glu	Leu	Glu	Glu	Met	Met	Leu	Val	Val	His	Met
	305					310					315				320	
	Pro	Arg	Phe	Arg	Ile	Glu	Asp	Gly	Phe	Ser	Leu	Lys	Glu	Gln	Leu	Gln
					325						330				335	
40	Asp	Met	Gly	Leu	Val	Asp	Leu	Phe	Ser	Pro	Glu	Lys	Ser	Lys	Leu	Pro
					340						345				350	
	Gly	Ile	Val	Ala	Glu	Gly	Arg	Asp	Asp	Leu	Tyr	Val	Ser	Asp	Ala	Phe
45					355						360				365	

His Lys Ala Phe Leu Glu Val Asn Glu Gly Ser Glu Ala Ala Ala
 370 375 380

5 Ser Thr Ala Val Val Ile Ala Gly Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415

10 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

15

20

25

30

35

40

45

50

55

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: Eisai Co., Ltd.
(B) STREET: 6-10, Koishikawa 4-chome, Bunkyo-ku
(C) CITY: Tokyo
(E) COUNTRY: Japan
(F) POSTAL CODE (ZIP): 112

(ii) TITLE OF INVENTION: Human Antithrombin III Mutants

(iii) NUMBER OF SEQUENCES: 81

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: JP 90488/92
(B) FILING DATE: 10-Apr-1992
(A) APPLICATION NUMBER: JP 31855/93
(B) FILING DATE: 22-Feb-1993

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1395 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 1..1395

(ix) FEATURE:

(A) NAME/KEY: sig_peptide
(B) LOCATION: 1..96

(ix) FEATURE:

(A) NAME/KEY: mat_peptide
(B) LOCATION: 97..1395

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ATG TAT TCC AAT GTG ATA GGA ACT GTA ACC TCT GGA AAA AGG AAG GTT
Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

48

EP 0 568 833 A1

	TAT CTT TTG TCC TTG CTG CTC ATT GGC TTC TGG GAC TGC GTG ACC TGT	96
	Tyr Leu Leu Ser Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys	
	-15 -10 -5	
5	CAC GGG AGC CCT GTG GAC ATC TGC ACA GCC AAG CCG CGG GAC ATT CCC	144
	His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro	
	1 5 10 15	
	ATG AAT CCC ATG TGC ATT TAC CGC TCC CCG GAG AAG AAG GCA ACT GAG	192
10	Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu	
	20 25 30	
	GAT GAG GGC TCA GAA CAA AAG ATC CCG GAG GCC ACC AAC CGG CGT GTC	240
	Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val	
	35 40 45	
15	TGG GAA CTG TCC AAG GCC AAT TCC CGC TTT GCT ACC ACT TTC TAT CAG	288
	Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Phe Tyr Gln	
	50 55 60	
	CAC CTG GCA GAT TCC AAG AAT GAC AAT GAT AAC ATT TTC CTG TCA CCC	336
20	His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro	
	65 70 75 80	
	CTG AGT ATC TCC ACG GCT TTT GCT ATG ACC AAG CTG GGT GCC TGT AAT	384
	Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn	
	85 90 95	
25	GAC ACC CTC CAG CAA CTG ATG GAG GTA TTT AAG TTT GAC ACC ATA TCT	432
	Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser	
	100 105 110	
	GAG AAA ACA TCT GAT CAG ATC CAC TTC TTC TTT GCC AAA CTG AAC TGC	480
	Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys	
	115 120 125	
30	CGA CTC TAT CGA AAA GCC AAC AAA TCC TCC AAG TTA GTA TCA GCC AAT	528
	Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn	
	130 135 140	
35	CGC CTT TTT GGA GAC AAA TCC CTT ACC TTC AAT GAG ACC TAC CAG GAC	576
	Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp	
	145 150 155 160	
	ATC AGT GAG TTG GTA TAT GGA GCC AAG CTC CAG CCC CTG GAC TTC AAG	624
	Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys	
	165 170 175	
40	GAA AAT GCA GAG CAA TCC AGA GCG GCC ATC AAC AAA TGG GTG TCC AAT	672
	Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn	
	180 185 190	
	AAG ACC GAA GGC CGA ATC ACC GAT GTC ATT CCC TCG GAA GCC ATC AAT	720
45	Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn	
	195 200 205	
	GAG CTC ACT GTT CTG GTG CTG GTT AAC ACC ATT TAC TTC AAG GGC CTG	768
	Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu	
	210 215 220	
50	TGG AAG TCA AAG TTC AGC CCT GAG AAC ACA AGG AAG GAA CTG TTC TAC	816
	Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr	
	225 230 235 240	

EP 0 568 833 A1

	AAG GCT GAT GGA GAG TCG TGT TCA GCA TCT ATG ATG TAC CAG GAA GGC	864
	Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly	
	245 250 255	
5	AAG TTC CGT TAT CGG CGC GTG GCT GAA GGC ACC CAG GTG CTT GAG TTG	912
	Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu	
	260 265 270	
	CCC TTC AAA GGT GAT GAC ATC ACC ATG GTC CTC ATC TTG CCC AAG CCT	960
	Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro	
10	275 280 285	
	GAG AAG AGC CTG GCC AAG GTT GAG AAG GAA CTC ACC CCA GAA GTG CTG	1008
	Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu	
	290 295 300	
15	CAG GAG TGG CTG GAT GAA TTG GAG GAG ATG ATG CTG GTG GTC CAC ATG	1056
	Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met	
	305 310 315 320	
	CCC CGC TTC CGC ATT GAG GAC GGC TTC AGT TTG AAG GAG CAG CTG CAA	1104
	Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln	
20	325 330 335	
	GAC ATG GGC CTT GTC GAT CTG TTC AGC CCT GAA AAG TCC AAA CTC CCA	1152
	Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro	
	340 345 350	
25	GGT ATT GTT GCA GAA GGC CGA GAT GAC CTC TAT GTC TCA GAT GCA TTC	1200
	Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe	
	355 360 365	
	CAT AAG GCA TTT CTT GAG GTA AAC GAA GAA GGC AGT GAA GCA GCT GCA	1248
	His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala	
30	370 375 380	
	AGT ACC GCT GTT GTG ATT GCT GGC CGT TCG CTA AAC CCC AAC AGG GTG	1296
	Ser Thr Ala Val Val Ile Ala Gly Arg Ser Leu Asn Pro Asn Arg Val	
	385 390 395 400	
35	ACT TTC AAG GCC AAC AGG CCT TTC CTG GTT TTT ATA AGA GAA GTT CCT	1344
	Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro	
	405 410 415	
	CTG AAC ACT ATT ATC TTC ATG GGC AGA GTA GCC AAC CCT TGT GTT AAG	1392
	Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys	
40	420 425 430	
	TAA	1395

45 (2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 464 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: protein

55

EP 0 568 833 A1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

5	Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val	-32 -30 -25 -20
	Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys	-15 -10 -5
	His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro	1 5 10 15
10	Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu	20 25 30
	Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val	35 40 45
15	Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln	50 55 60
	His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro	65 70 75 80
20	Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn	85 90 95
	Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser	100 105 110
25	Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys	115 120 125
	Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn	130 135 140
30	Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp	145 150 155 160
	Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys	165 170 175
35	Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn	180 185 190
	Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn	195 200 205
40	Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu	210 215 220
	Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr	225 230 235 240
45	Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly	245 250 255
	Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu	260 265 270
50	Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro	275 280 285

55

EP 0 568 833 A1

Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 5 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 10 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 15 Ser Thr Ala Val Val Ile Ala Gly Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 20 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 3:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 35 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 40 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30
 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45
 45 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60
 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80
 50 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95

55

EP 0 568 833 A1

	Asp	Thr	Leu	Gln	Gln	Leu	Met	Glu	Val	Phe	Lys	Phe	Asp	Thr	Ile	Ser	
				100					105					110			
5	Glu	Lys	Thr	Ser	Asp	Gln	Ile	His	Phe	Phe	Phe	Ala	Lys	Leu	Asn	Cys	
			115					120					125				
	Arg	Leu	Tyr	Arg	Lys	Ala	Asn	Lys	Ser	Ser	Lys	Leu	Val	Ser	Ala	Asn	
		130					135					140					
10	Arg	Leu	Phe	Gly	Asp	Lys	Ser	Leu	Thr	Phe	Asn	Glu	Thr	Tyr	Gln	Asp	
	145					150					155					160	
	Ile	Ser	Glu	Leu	Val	Tyr	Gly	Ala	Lys	Leu	Gln	Pro	Leu	Asp	Phe	Lys	
					165					170					175		
15	Glu	Asn	Ala	Glu	Gln	Ser	Arg	Ala	Ala	Ile	Asn	Lys	Trp	Val	Ser	Asn	
				180					185					190			
	Lys	Thr	Glu	Gly	Arg	Ile	Thr	Asp	Val	Ile	Pro	Ser	Glu	Ala	Ile	Asn	
			195					200					205				
20	Glu	Leu	Thr	Val	Leu	Val	Leu	Val	Asn	Thr	Ile	Tyr	Phe	Lys	Gly	Leu	
	210						215					220					
	Trp	Lys	Ser	Lys	Phe	Ser	Pro	Glu	Asn	Thr	Arg	Lys	Glu	Leu	Phe	Tyr	
	225					230					235					240	
	Lys	Ala	Asp	Gly	Glu	Ser	Cys	Ser	Ala	Ser	Met	Met	Tyr	Gln	Glu	Gly	
					245					250					255		
25	Lys	Phe	Arg	Tyr	Arg	Arg	Val	Ala	Glu	Gly	Thr	Gln	Val	Leu	Glu	Leu	
				260					265					270			
	Pro	Phe	Lys	Gly	Asp	Asp	Ile	Thr	Met	Val	Leu	Ile	Leu	Pro	Lys	Pro	
			275					280					285				
30	Glu	Lys	Ser	Leu	Ala	Lys	Val	Glu	Lys	Glu	Leu	Thr	Pro	Glu	Val	Leu	
		290					295					300					
	Gln	Glu	Trp	Leu	Asp	Glu	Leu	Glu	Glu	Met	Met	Leu	Val	Val	His	Met	
	305					310					315					320	
35	Pro	Arg	Phe	Arg	Ile	Glu	Asp	Gly	Phe	Ser	Leu	Lys	Glu	Gln	Leu	Gln	
					325					330					335		
	Asp	Met	Gly	Leu	Val	Asp	Leu	Phe	Ser	Pro	Glu	Lys	Ser	Lys	Leu	Pro	
				340					345					350			
40	Gly	Ile	Val	Ala	Glu	Gly	Arg	Asp	Asp	Leu	Tyr	Val	Ser	Asp	Ala	Phe	
			355					360					365				
	His	Lys	Ala	Phe	Leu	Glu	Val	Asn	Glu	Glu	Gly	Ser	Glu	Ala	Ala	Ala	
		370					375					380					
45	Ser	Thr	Ala	Val	Val	Ile	Ala	Pro	Arg	Ser	Leu	Asn	Pro	Asn	Arg	Val	
	385					390					395					400	
	Thr	Phe	Lys	Ala	Asn	Arg	Pro	Phe	Leu	Val	Phe	Ile	Arg	Glu	Val	Pro	
					405					410					415		
50	Leu	Asn	Thr	Ile	Ile	Phe	Met	Gly	Arg	Val	Ala	Asn	Pro	Cys	Val	Lys	
				420					425					430			

EP 0 568 833 A1

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 464 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

```

10 Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
   -32      -30      -25      -20

   Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
      -15      -10      -5

15 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
    1          5          10          15

   Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
      20          25          30

20 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
      35          40          45

   Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
      50          55          60

25 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
    65          70          75          80

   Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
      85          90          95

30 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
      100          105          110

   Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
      115          120          125

35 Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
    130          135          140

   Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
    145          150          155          160

   Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
      165          170          175

45 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
      180          185          190

   Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
      195          200          205

50 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
    210          215          220

```

EP 0 568 833 A1

Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
225 230 235 240

Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
245 250 255

Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
260 265 270

Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
275 280 285

Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
290 295 300

Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
355 360 365

His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
370 375 380

Ser Thr Ala Val Val Ile Phe Pro Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

EP 0 568 833 A1

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45
 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60
 5 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80
 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95
 10 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
 115 120 125
 15 Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 130 135 140
 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
 145 150 155 160
 20 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
 165 170 175
 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 180 185 190
 25 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 30 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 35 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 40 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 45 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 50 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365

55

EP 0 568 833 A1

His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
370 375 380

5 Ser Thr Ala Val Val Ile Ile Pro Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

10 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

25 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

30 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

35 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

40 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
115 120 125

45 Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140

Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160

50 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175

55

EP 0 568 833 A1

Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 180 185 190
 5 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 10 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 15 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 20 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 25 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 30 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 35 Ser Thr Ala Val Val Ile Gly Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 40 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 7:

45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 50 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

55

EP 0 568 833 A1

5 Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 10 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30
 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45
 15 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60
 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80
 20 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95
 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 25 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
 115 120 125
 Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 130 135 140
 30 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
 145 150 155 160
 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
 165 170 175
 35 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 180 185 190
 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 40 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 45 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 50 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300

EP 0 568 833 A1

Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
355 360 365

His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
370 375 380

Ser Thr Ala Val Val Ile Tyr Pro Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

EP 0 568 833 A1

	Glu	Lys	Thr	Ser	Asp	Gln	Ile	His	Phe	Phe	Phe	Ala	Lys	Leu	Asn	Cys
			115					120					125			
5	Arg	Leu	Tyr	Arg	Lys	Ala	Asn	Lys	Ser	Ser	Lys	Leu	Val	Ser	Ala	Asn
		130					135					140				
	Arg	Leu	Phe	Gly	Asp	Lys	Ser	Leu	Thr	Phe	Asn	Glu	Thr	Tyr	Gln	Asp
	145					150					155					160
10	Ile	Ser	Glu	Leu	Val	Tyr	Gly	Ala	Lys	Leu	Gln	Pro	Leu	Asp	Phe	Lys
					165					170					175	
	Glu	Asn	Ala	Glu	Gln	Ser	Arg	Ala	Ala	Ile	Asn	Lys	Trp	Val	Ser	Asn
				180					185					190		
15	Lys	Thr	Glu	Gly	Arg	Ile	Thr	Asp	Val	Ile	Pro	Ser	Glu	Ala	Ile	Asn
			195					200					205			
	Glu	Leu	Thr	Val	Leu	Val	Leu	Val	Asn	Thr	Ile	Tyr	Phe	Lys	Gly	Leu
		210					215					220				
20	Trp	Lys	Ser	Lys	Phe	Ser	Pro	Glu	Asn	Thr	Arg	Lys	Glu	Leu	Phe	Tyr
	225					230					235					240
	Lys	Ala	Asp	Gly	Glu	Ser	Cys	Ser	Ala	Ser	Met	Met	Tyr	Gln	Glu	Gly
					245					250					255	
25	Lys	Phe	Arg	Tyr	Arg	Arg	Val	Ala	Glu	Gly	Thr	Gln	Val	Leu	Glu	Leu
				260					265					270		
	Pro	Phe	Lys	Gly	Asp	Asp	Ile	Thr	Met	Val	Leu	Ile	Leu	Pro	Lys	Pro
			275					280					285			
30	Glu	Lys	Ser	Leu	Ala	Lys	Val	Glu	Lys	Glu	Leu	Thr	Pro	Glu	Val	Leu
		290					295					300				
	Gln	Glu	Trp	Leu	Asp	Glu	Leu	Glu	Glu	Met	Met	Leu	Val	Val	His	Met
	305					310				315						320
35	Pro	Arg	Phe	Arg	Ile	Glu	Asp	Gly	Phe	Ser	Leu	Lys	Glu	Gln	Leu	Gln
					325					330					335	
	Asp	Met	Gly	Leu	Val	Asp	Leu	Phe	Ser	Pro	Glu	Lys	Ser	Lys	Leu	Pro
				340					345					350		
40	Gly	Ile	Val	Ala	Glu	Gly	Arg	Asp	Asp	Leu	Tyr	Val	Ser	Asp	Ala	Phe
			355					360					365			
	His	Lys	Ala	Phe	Leu	Glu	Val	Asn	Glu	Glu	Gly	Ser	Glu	Ala	Ala	Ala
		370					375					380				
45	Ser	Thr	Ala	Val	Val	Ile	Trp	Pro	Arg	Ser	Leu	Asn	Pro	Asn	Arg	Val
		385				390					395				400	
	Thr	Phe	Lys	Ala	Asn	Arg	Pro	Phe	Leu	Val	Phe	Ile	Arg	Glu	Val	Pro
					405					410					415	
50	Leu	Asn	Thr	Ile	Ile	Phe	Met	Gly	Arg	Val	Ala	Asn	Pro	Cys	Val	Lys
					420				425					430		

55

EP 0 568 833 A1

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 464 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

```

10 Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
   -32   -30           -25           -20

   Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
   -15           -10           -5

15 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
    1           5           10           15

   Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
           20           25           30

20 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
           35           40           45

   Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
           50           55           60

25 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
    65           70           75           80

   Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
           85           90           95

30 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
           100           105           110

   Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
           115           120           125

35 Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
    130           135           140

   Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
    145           150           155           160

40 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
           165           170           175

   Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
           180           185           190

45 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
           195           200           205

   Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
    210           215           220

50 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
    225           230           235           240

   Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly

```

EP 0 568 833 A1

245 250 255

5 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
260 265 270

Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
275 280 285

10 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
290 295 300

Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

15 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

20 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
355 360 365

His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
370 375 380

Ser Thr Ala Val Val Ile Val Pro Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400

25 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

Leu Asn Thr Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

30

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

40 Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

45 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

50 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

55

EP 0 568 833 A1

	Trp	Glu	Leu	Ser	Lys	Ala	Asn	Ser	Arg	Phe	Ala	Thr	Thr	Phe	Tyr	Gln	
		50					55					60					
5	His	Leu	Ala	Asp	Ser	Lys	Asn	Asp	Asn	Asp	Asn	Ile	Phe	Leu	Ser	Pro	
	65					70				75						80	
	Leu	Ser	Ile	Ser	Thr	Ala	Phe	Ala	Met	Thr	Lys	Leu	Gly	Ala	Cys	Asn	
					85					90					95		
10	Asp	Thr	Leu	Gln	Gln	Leu	Met	Glu	Val	Phe	Lys	Phe	Asp	Thr	Ile	Ser	
				100					105					110			
	Glu	Lys	Thr	Ser	Asp	Gln	Ile	His	Phe	Phe	Phe	Ala	Lys	Leu	Asn	Cys	
			115				120						125				
15	Arg	Leu	Tyr	Arg	Lys	Ala	Asn	Lys	Ser	Ser	Lys	Leu	Val	Ser	Ala	Asn	
	130						135					140					
	Arg	Leu	Phe	Gly	Asp	Lys	Ser	Leu	Thr	Phe	Asn	Glu	Thr	Tyr	Gln	Asp	
	145					150					155					160	
20	Ile	Ser	Glu	Leu	Val	Tyr	Gly	Ala	Lys	Leu	Gln	Pro	Leu	Asp	Phe	Lys	
				165						170					175		
	Glu	Asn	Ala	Glu	Gln	Ser	Arg	Ala	Ala	Ile	Asn	Lys	Trp	Val	Ser	Asn	
			180						185					190			
25	Lys	Thr	Glu	Gly	Arg	Ile	Thr	Asp	Val	Ile	Pro	Ser	Glu	Ala	Ile	Asn	
		195					200						205				
	Glu	Leu	Thr	Val	Leu	Val	Leu	Val	Asn	Thr	Ile	Tyr	Phe	Lys	Gly	Leu	
	210						215					220					
30	Trp	Lys	Ser	Lys	Phe	Ser	Pro	Glu	Asn	Thr	Arg	Lys	Glu	Leu	Phe	Tyr	
	225					230					235					240	
	Lys	Ala	Asp	Gly	Glu	Ser	Cys	Ser	Ala	Ser	Met	Met	Tyr	Gln	Glu	Gly	
				245						250					255		
35	Lys	Phe	Arg	Tyr	Arg	Arg	Val	Ala	Glu	Gly	Thr	Gln	Val	Leu	Glu	Leu	
			260						265					270			
	Pro	Phe	Lys	Gly	Asp	Asp	Ile	Thr	Met	Val	Leu	Ile	Leu	Pro	Lys	Pro	
		275					280						285				
40	Glu	Lys	Ser	Leu	Ala	Lys	Val	Glu	Lys	Glu	Leu	Thr	Pro	Glu	Val	Leu	
		290					295					300					
	Gln	Glu	Trp	Leu	Asp	Glu	Leu	Glu	Glu	Met	Met	Leu	Val	Val	His	Met	
	305					310					315					320	
45	Pro	Arg	Phe	Arg	Ile	Glu	Asp	Gly	Phe	Ser	Leu	Lys	Glu	Gln	Leu	Gln	
				325						330					335		
	Asp	Met	Gly	Leu	Val	Asp	Leu	Phe	Ser	Pro	Glu	Lys	Ser	Lys	Leu	Pro	
			340						345					350			
50	Gly	Ile	Val	Ala	Glu	Gly	Arg	Asp	Asp	Leu	Tyr	Val	Ser	Asp	Ala	Phe	
		355					360						365				
	His	Lys	Ala	Phe	Leu	Glu	Val	Asn	Glu	Glu	Gly	Ser	Glu	Ala	Ala	Ala	
		370					375					380					

EP 0 568 833 A1

Ser Thr Ala Val Val Ile Leu Pro Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400
Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415
Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20
Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5
His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15
Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30
Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45
Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60
His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80
Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95
Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110
Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
115 120 125
Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140
Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160
Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175
Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190

EP 0 568 833 A1

Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195 200 205

Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
210 215 220

Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
225 230 235 240

Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
245 250 255

Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
260 265 270

Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
275 280 285

Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
290 295 300

Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

Gly Ile Val Ala Glu Gly Arg Asp Leu Tyr Val Ser Asp Ala Phe
355 360 365

His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
370 375 380

Ser Thr Ala Val Val Ala Val Pro Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 464 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

EP 0 568 833 A1

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 5 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30
 10 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45
 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60
 15 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80
 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95
 20 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
 115 120 125
 25 Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 130 135 140
 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
 145 150 155 160
 30 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
 165 170 175
 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 180 185 190
 35 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 40 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 45 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 50 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320

EP 0 568 833 A1

Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

5 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
355 360 365

10 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
370 375 380

Ser Thr Ala Val Val Leu Phe Pro Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400

15 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

20 (2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

30 Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

35 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

40 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

45 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

50 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
115 120 125

55

EP 0 568 833 A1

	Arg	Leu	Tyr	Arg	Lys	Ala	Asn	Lys	Ser	Ser	Lys	Leu	Val	Ser	Ala	Asn
	130						135					140				
5	Arg	Leu	Phe	Gly	Asp	Lys	Ser	Leu	Thr	Phe	Asn	Glu	Thr	Tyr	Gln	Asp
	145					150					155					160
	Ile	Ser	Glu	Leu	Val	Tyr	Gly	Ala	Lys	Leu	Gln	Pro	Leu	Asp	Phe	Lys
					165					170					175	
10	Glu	Asn	Ala	Glu	Gln	Ser	Arg	Ala	Ala	Ile	Asn	Lys	Trp	Val	Ser	Asn
				180					185					190		
	Lys	Thr	Glu	Gly	Arg	Ile	Thr	Asp	Val	Ile	Pro	Ser	Glu	Ala	Ile	Asn
			195					200					205			
15	Glu	Leu	Thr	Val	Leu	Val	Leu	Val	Asn	Thr	Ile	Tyr	Phe	Lys	Gly	Leu
	210						215					220				
	Trp	Lys	Ser	Lys	Phe	Ser	Pro	Glu	Asn	Thr	Arg	Lys	Glu	Leu	Phe	Tyr
	225					230					235					240
20	Lys	Ala	Asp	Gly	Glu	Ser	Cys	Ser	Ala	Ser	Met	Met	Tyr	Gln	Glu	Gly
					245					250					255	
	Lys	Phe	Arg	Tyr	Arg	Arg	Val	Ala	Glu	Gly	Thr	Gln	Val	Leu	Glu	Leu
				260					265					270		
25	Pro	Phe	Lys	Gly	Asp	Asp	Ile	Thr	Met	Val	Leu	Ile	Leu	Pro	Lys	Pro
			275					280					285			
	Glu	Lys	Ser	Leu	Ala	Lys	Val	Glu	Lys	Glu	Leu	Thr	Pro	Glu	Val	Leu
		290					295					300				
30	Gln	Glu	Trp	Leu	Asp	Glu	Leu	Glu	Glu	Met	Met	Leu	Val	Val	His	Met
	305					310					315					320
	Pro	Arg	Phe	Arg	Ile	Glu	Asp	Gly	Phe	Ser	Leu	Lys	Glu	Gln	Leu	Gln
					325					330					335	
35	Asp	Met	Gly	Leu	Val	Asp	Leu	Phe	Ser	Pro	Glu	Lys	Ser	Lys	Leu	Pro
				340					345					350		
	Gly	Ile	Val	Ala	Glu	Gly	Arg	Asp	Asp	Leu	Tyr	Val	Ser	Asp	Ala	Phe
			355					360					365			
40	His	Lys	Ala	Phe	Leu	Glu	Val	Asn	Glu	Glu	Gly	Ser	Glu	Ala	Ala	Ala
		370					375					380				
	Ser	Thr	Ala	Val	Val	Ala	Tyr	Pro	Arg	Ser	Leu	Asn	Pro	Asn	Arg	Val
	385					390					395					400
45	Thr	Phe	Lys	Ala	Asn	Arg	Pro	Phe	Leu	Val	Phe	Ile	Arg	Glu	Val	Pro
					405					410					415	
	Leu	Asn	Thr	Ile	Ile	Phe	Met	Gly	Arg	Val	Ala	Asn	Pro	Cys	Val	Lys
				420					425					430		

(2) INFORMATION FOR SEQ ID NO: 14:

EP 0 568 833 A1

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

5	Met	Tyr	Ser	Asn	Val	Ile	Gly	Thr	Val	Thr	Ser	Gly	Lys	Arg	Lys	Val
10	-32		-30				-25					-20				
	Tyr	Leu	Leu	Ser	Leu	Leu	Leu	Ile	Gly	Phe	Trp	Asp	Cys	Val	Thr	Cys
	-15						-10					-5				
15	His	Gly	Ser	Pro	Val	Asp	Ile	Cys	Thr	Ala	Lys	Pro	Arg	Asp	Ile	Pro
	1				5					10					15	
	Met	Asn	Pro	Met	Cys	Ile	Tyr	Arg	Ser	Pro	Glu	Lys	Lys	Ala	Thr	Glu
				20					25					30		
20	Asp	Glu	Gly	Ser	Glu	Gln	Lys	Ile	Pro	Glu	Ala	Thr	Asn	Arg	Arg	Val
			35				40						45			
	Trp	Glu	Leu	Ser	Lys	Ala	Asn	Ser	Arg	Phe	Ala	Thr	Thr	Phe	Tyr	Gln
		50					55					60				
25	His	Leu	Ala	Asp	Ser	Lys	Asn	Asp	Asn	Asp	Asn	Ile	Phe	Leu	Ser	Pro
	65					70				75						80
	Leu	Ser	Ile	Ser	Thr	Ala	Phe	Ala	Met	Thr	Lys	Leu	Gly	Ala	Cys	Asn
					85					90					95	
30	Asp	Thr	Leu	Gln	Gln	Leu	Met	Glu	Val	Phe	Lys	Phe	Asp	Thr	Ile	Ser
				100					105					110		
	Glu	Lys	Thr	Ser	Asp	Gln	Ile	His	Phe	Phe	Phe	Ala	Lys	Leu	Asn	Cys
			115				120						125			
35	Arg	Leu	Tyr	Arg	Lys	Ala	Asn	Lys	Ser	Ser	Lys	Leu	Val	Ser	Ala	Asn
		130					135					140				
	Arg	Leu	Phe	Gly	Asp	Lys	Ser	Leu	Thr	Phe	Asn	Glu	Thr	Tyr	Gln	Asp
	145				150					155					160	
40	Ile	Ser	Glu	Leu	Val	Tyr	Gly	Ala	Lys	Leu	Gln	Pro	Leu	Asp	Phe	Lys
				165					170					175		
	Glu	Asn	Ala	Glu	Gln	Ser	Arg	Ala	Ala	Ile	Asn	Lys	Trp	Val	Ser	Asn
				180				185						190		
45	Lys	Thr	Glu	Gly	Arg	Ile	Thr	Asp	Val	Ile	Pro	Ser	Glu	Ala	Ile	Asn
			195				200						205			
	Glu	Leu	Thr	Val	Leu	Val	Leu	Val	Asn	Thr	Ile	Tyr	Phe	Lys	Gly	Leu
		210					215					220				
50	Trp	Lys	Ser	Lys	Phe	Ser	Pro	Glu	Asn	Thr	Arg	Lys	Glu	Leu	Phe	Tyr
	225				230						235				240	
	Lys	Ala	Asp	Gly	Glu	Ser	Cys	Ser	Ala	Ser	Met	Met	Tyr	Gln	Glu	Gly
				245					250						255	

55

5 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 10 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 15 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 20 Ser Thr Ala Val Val Ala Trp Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 25 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

40 Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 45 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30
 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45
 50 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60

EP 0 568 833 A1

	His	Leu	Ala	Asp	Ser	Lys	Asn	Asp	Asn	Asp	Asn	Ile	Phe	Leu	Ser	Pro
	65					70					75					80
5	Leu	Ser	Ile	Ser	Thr	Ala	Phe	Ala	Met	Thr	Lys	Leu	Gly	Ala	Cys	Asn
					85					90					95	
	Asp	Thr	Leu	Gln	Gln	Leu	Met	Glu	Val	Phe	Lys	Phe	Asp	Thr	Ile	Ser
				100					105					110		
10	Glu	Lys	Thr	Ser	Asp	Gln	Ile	His	Phe	Phe	Phe	Ala	Lys	Leu	Asn	Cys
			115					120					125			
	Arg	Leu	Tyr	Arg	Lys	Ala	Asn	Lys	Ser	Ser	Lys	Leu	Val	Ser	Ala	Asn
	130						135					140				
15	Arg	Leu	Phe	Gly	Asp	Lys	Ser	Leu	Thr	Phe	Asn	Glu	Thr	Tyr	Gln	Asp
	145					150					155					160
	Ile	Ser	Glu	Leu	Val	Tyr	Gly	Ala	Lys	Leu	Gln	Pro	Leu	Asp	Phe	Lys
					165					170					175	
20	Glu	Asn	Ala	Glu	Gln	Ser	Arg	Ala	Ala	Ile	Asn	Lys	Trp	Val	Ser	Asn
				180					185					190		
	Lys	Thr	Glu	Gly	Arg	Ile	Thr	Asp	Val	Ile	Pro	Ser	Glu	Ala	Ile	Asn
			195					200					205			
25	Glu	Leu	Thr	Val	Leu	Val	Leu	Val	Asn	Thr	Ile	Tyr	Phe	Lys	Gly	Leu
	210						215					220				
	Trp	Lys	Ser	Lys	Phe	Ser	Pro	Glu	Asn	Thr	Arg	Lys	Glu	Leu	Phe	Tyr
	225					230					235					240
30	Lys	Ala	Asp	Gly	Glu	Ser	Cys	Ser	Ala	Ser	Met	Met	Tyr	Gln	Glu	Gly
					245					250					255	
	Lys	Phe	Arg	Tyr	Arg	Arg	Val	Ala	Glu	Gly	Thr	Gln	Val	Leu	Glu	Leu
				260					265					270		
35	Pro	Phe	Lys	Gly	Asp	Asp	Ile	Thr	Met	Val	Leu	Ile	Leu	Pro	Lys	Pro
			275					280					285			
	Glu	Lys	Ser	Leu	Ala	Lys	Val	Glu	Lys	Glu	Leu	Thr	Pro	Glu	Val	Leu
			290				295					300				
40	Gln	Glu	Trp	Leu	Asp	Glu	Leu	Glu	Glu	Met	Met	Leu	Val	Val	His	Met
	305					310					315					320
	Pro	Arg	Phe	Arg	Ile	Glu	Asp	Gly	Phe	Ser	Leu	Lys	Glu	Gln	Leu	Gln
					325					330					335	
45	Asp	Met	Gly	Leu	Val	Asp	Leu	Phe	Ser	Pro	Glu	Lys	Ser	Lys	Leu	Pro
				340					345					350		
	Gly	Ile	Val	Ala	Glu	Gly	Arg	Asp	Asp	Leu	Tyr	Val	Ser	Asp	Ala	Phe
			355					360						365		
50	His	Lys	Ala	Phe	Leu	Glu	Val	Asn	Glu	Glu	Gly	Ser	Glu	Ala	Ala	Ala
							375					380				
	Ser	Thr	Ala	Val	Val	Leu	Trp	Pro	Arg	Ser	Leu	Asn	Pro	Asn	Arg	Val
	385					390					395					400

55

EP 0 568 833 A1

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

5 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 16:

10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

20 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

25 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

30 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

35 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

40 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
115 120 125

Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140

45 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160

Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175

50 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190

55

EP 0 568 833 A1

Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 5 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 10 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 15 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 20 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 25 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 30 Ser Thr Ala Val Val Ala Val Gly Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 35 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 50 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5

EP 0 568 833 A1

1 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 5 1 5 10 15
 20 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 5 20 25 30
 35 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 40 45
 50 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 10 50 55 60
 65 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 70 75 80
 85 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 15 85 90 95
 100 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 105 110
 115 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
 120 120 125
 130 Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 135 140
 145 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
 150 155 160
 165 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
 170 175
 180 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 185 190
 195 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 200 205
 210 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 215 220
 225 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 230 235 240
 245 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 250 255
 260 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 265 270
 275 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 280 285
 290 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 295 300
 305 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 310 315 320
 325 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 330 335

EP 0 568 833 A1

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 5 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ala Ile Gly Arg Ser Leu Asn Pro Asn Arg Val
 10 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 15 420 425 430

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
 Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 30 -15 -10 -5
 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 35 20 25 30
 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45
 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 40 50 55 60
 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80
 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 45 85 90 95
 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
 50 115 120 125

EP 0 568 833 A1

Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140

Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160

Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175

Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190

Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195 200 205

Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
210 215 220

Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
225 230 235 240

Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
245 250 255

Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
260 265 270

Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
275 280 285

Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
290 295 300

Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
355 360 365

His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
370 375 380

Ser Thr Ala Val Val Ala Leu Gly Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids

EP 0 568 833 A1

(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

```

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32      -30      -25      -20
Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15      -10      -5
His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1         5         10        15
Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
15        20        25        30
Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35        40        45
Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50        55        60
His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65        70        75        80
Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85        90        95
Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100       105       110
Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
115       120       125
Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130       135       140
Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145       150       155       160
Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165       170       175
Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180       185       190
Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195       200       205
Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
210       215       220
Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
225       230       235       240
Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
245       250       255
Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
260       265       270

```

EP 0 568 833 A1

Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
275 280 285

5 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
290 295 300

Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

10 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

15 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
355 360 365

His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
370 375 380

20 Ser Thr Ala Val Val Gly Leu Gly Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

25 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 20:

30

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 464 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

40

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

45

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

50

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

55

EP 0 568 833 A1

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80
 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95
 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
 115 120 125
 Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 130 135 140
 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
 145 150 155 160
 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
 165 170 175
 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 180 185 190
 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Gly
 370 375 380
 Ser Thr Ala Val Val Ile Ala Gly Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400

EP 0 568 833 A1

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415
Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20
Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5
His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15
Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30
Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45
Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60
His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80
Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95
Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110
Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
115 120 125
Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140
Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160
Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175
Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190
Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195 200 205

EP 0 568 833 A1

5
10
15
20
25
30
35

Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
210 215 220

Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
225 230 235 240

Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
245 250 255

Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
260 265 270

Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
275 280 285

Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
290 295 300

Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
355 360 365

His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
370 375 380

Ser Thr Ala Val Pro Ile Ala Gly Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 22:

40
45
50
55

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

EP 0 568 833 A1

1 His Gly Ser Pro Val 5 Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro 15
 5 Met Asn Pro Met Cys Ile Tyr Arg Ser 20 25 Pro Glu Lys Lys Ala Thr Glu 30
 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val 35 40 45
 10 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Phe Tyr Gln 50 55 60
 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro 65 70 75 80
 15 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn 85 90 95
 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser 100 105 110
 20 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys 115 120 125
 Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn 130 135 140
 25 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp 145 150 155 160
 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys 165 170 175
 30 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn 180 185 190
 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn 195 200 205
 35 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu 210 215 220
 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr 225 230 235 240
 40 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly 245 250 255
 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu 260 265 270
 45 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu 290 295 300
 50 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met 305 310 315 320
 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln 325 330 335

EP 0 568 833 A1

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Phe Val Ile Ala Gly Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30
 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45
 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60
 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80
 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95
 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
 115 120 125
 Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 130 135 140

EP 0 568 833 A1

	Arg	Leu	Phe	Gly	Asp	Lys	Ser	Leu	Thr	Phe	Asn	Glu	Thr	Tyr	Gln	Asp	145	150	155	160
	Ile	Ser	Glu	Leu	Val	Tyr	Gly	Ala	Lys	Leu	Gln	Pro	Leu	Asp	Phe	Lys	165	170	175	
5	Glu	Asn	Ala	Glu	Gln	Ser	Arg	Ala	Ala	Ile	Asn	Lys	Trp	Val	Ser	Asn	180	185	190	
	Lys	Thr	Glu	Gly	Arg	Ile	Thr	Asp	Val	Ile	Pro	Ser	Glu	Ala	Ile	Asn	195	200	205	
10	Glu	Leu	Thr	Val	Leu	Val	Leu	Val	Asn	Thr	Ile	Tyr	Phe	Lys	Gly	Leu	210	215	220	
	Trp	Lys	Ser	Lys	Phe	Ser	Pro	Glu	Asn	Thr	Arg	Lys	Glu	Leu	Phe	Tyr	225	230	235	240
15	Lys	Ala	Asp	Gly	Glu	Ser	Cys	Ser	Ala	Ser	Met	Met	Tyr	Gln	Glu	Gly	245	250	255	
	Lys	Phe	Arg	Tyr	Arg	Arg	Val	Ala	Glu	Gly	Thr	Gln	Val	Leu	Glu	Leu	260	265	270	
20	Pro	Phe	Lys	Gly	Asp	Asp	Ile	Thr	Met	Val	Leu	Ile	Leu	Pro	Lys	Pro	275	280	285	
	Glu	Lys	Ser	Leu	Ala	Lys	Val	Glu	Lys	Glu	Leu	Thr	Pro	Glu	Val	Leu	290	295	300	
25	Gln	Glu	Trp	Leu	Asp	Glu	Leu	Glu	Glu	Met	Met	Leu	Val	Val	His	Met	305	310	315	320
	Pro	Arg	Phe	Arg	Ile	Glu	Asp	Gly	Phe	Ser	Leu	Lys	Glu	Gln	Leu	Gln	325	330	335	
30	Asp	Met	Gly	Leu	Val	Asp	Leu	Phe	Ser	Pro	Glu	Lys	Ser	Lys	Leu	Pro	340	345	350	
	Gly	Ile	Val	Ala	Glu	Gly	Arg	Asp	Asp	Leu	Tyr	Val	Ser	Asp	Ala	Phe	355	360	365	
35	His	Lys	Ala	Phe	Leu	Glu	Val	Asn	Glu	Glu	Gly	Ser	Glu	Ala	Ala	Ala	370	375	380	
	Ser	Thr	Ala	Val	Val	Ile	Ala	Gly	Arg	Ser	Leu	Asn	Pro	Glu	Arg	Val	385	390	395	400
40	Thr	Phe	Lys	Ala	Asn	Arg	Pro	Phe	Leu	Val	Phe	Ile	Arg	Glu	Val	Pro	405	410	415	
	Leu	Asn	Thr	Ile	Ile	Phe	Met	Gly	Arg	Val	Ala	Asn	Pro	Cys	Val	Lys	420	425	430	

(2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 464 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

EP 0 568 833 A1

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

```

5      Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
      -32      -30      -25      -20

      Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
      -15      -10      -5

10     His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
      1          5          10          15

      Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
      20          25          30

15     Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
      35          40          45

      Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
      50          55          60

20     His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
      65          70          75          80

      Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
      85          90          95

25     Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
      100         105         110

      Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
      115         120         125

30     Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
      130         135         140

      Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
      145         150         155         160

35     Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
      165         170         175

      Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
      180         185         190

40     Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
      195         200         205

      Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
      210         215         220

45     Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
      225         230         235         240

      Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
      245         250         255

50     Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
      260         265         270

```

55

EP 0 568 833 A1

Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
275 280 285

5 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
290 295 300

Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

10 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

15 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
355 360 365

His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
370 375 380

20 Ser Thr Ala Val Val Ile Ala Gly Arg Ser Leu Asn Pro Arg Arg Val
385 390 395 400

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

25 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

40 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

45 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

55 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

EP 0 568 833 A1

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95
 5 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
 115 120 125
 10 Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 130 135 140
 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
 145 150 155 160
 15 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
 165 170 175
 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 180 185 190
 20 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 25 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 30 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 35 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 40 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 45 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ile Ala Gly Arg Ser Leu Asn Arg Arg Arg Val
 385 390 395 400
 50 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 55

EP 0 568 833 A1

Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

5

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 464 amino acids

(B) TYPE: amino acid

10

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

15

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

20

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

25

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

30

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

35

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Gln Leu Asn Cys
115 120 125

40

Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140

Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160

45

Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175

Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190

50

Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195 200 205

55

EP 0 568 833 A1

Glu 210	Leu	Thr	Val	Leu	Val	Leu	Val	Asn	Thr	Ile	Tyr	Phe	Lys	Gly	Leu
Trp 225	Lys	Ser	Lys	Phe	Ser	Pro	Glu	Asn	Thr	Arg	Lys	Glu	Leu	Phe	Tyr
Lys	Ala	Asp	Gly	Glu	Ser	Cys	Ser	Ala	Ser	Met	Met	Tyr	Gln	Glu	Gly
Lys	Phe	Arg	Tyr	Arg	Arg	Val	Ala	Glu	Gly	Thr	Gln	Val	Leu	Glu	Leu
Pro	Phe	Lys	Gly	Asp	Asp	Ile	Thr	Met	Val	Leu	Ile	Leu	Pro	Lys	Pro
Glu	Lys	Ser	Leu	Ala	Lys	Val	Glu	Lys	Glu	Leu	Thr	Pro	Glu	Val	Leu
Gln	Glu	Trp	Leu	Asp	Glu	Leu	Glu	Glu	Met	Met	Leu	Val	Val	His	Met
Pro	Arg	Phe	Arg	Ile	Glu	Asp	Gly	Phe	Ser	Leu	Lys	Glu	Gln	Leu	Gln
Asp	Met	Gly	Leu	Val	Asp	Leu	Phe	Ser	Pro	Glu	Lys	Ser	Lys	Leu	Pro
Gly	Ile	Val	Ala	Glu	Gly	Arg	Asp	Asp	Leu	Tyr	Val	Ser	Asp	Ala	Phe
His	Lys	Ala	Phe	Leu	Glu	Val	Asn	Glu	Glu	Gly	Ser	Glu	Ala	Ala	Ala
Ser	Thr	Ala	Val	Val	Ile	Ala	Pro	Arg	Ser	Leu	Asn	Pro	Asn	Arg	Val
Thr	Phe	Lys	Ala	Asn	Arg	Pro	Phe	Leu	Val	Phe	Ile	Arg	Glu	Val	Pro
Leu	Asn	Thr	Ile	Ile	Phe	Met	Gly	Arg	Val	Ala	Asn	Pro	Cys	Val	Lys

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

EP 0 568 833 A1

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Gln Leu Asn Cys
115 120 125

Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140

Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160

Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175

Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190

Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195 200 205

Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
210 215 220

Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
225 230 235 240

Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
245 250 255

Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
260 265 270

Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
275 280 285

Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
290 295 300

Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

EP 0 568 833 A1

Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ile Phe Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30
 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 35 40 45
 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60
 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80
 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95
 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Gln Leu Asn Cys
 115 120 125
 Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 130 135 140

EP 0 568 833 A1

Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
 145 150 155 160
 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
 165 170 175
 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 180 185 190
 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ile Val Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 29:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 464 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

EP 0 568 833 A1

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

```

5      Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
      -32      -30      -25      -20

      Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
      -15      -10      -5

10     His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
      1          5          10          15

      Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
      20          25          30

15     Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
      35          40          45

      Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
      50          55          60

20     His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
      65          70          75          80

      Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
      85          90          95

25     Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
      100          105          110

      Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Gln Leu Asn Cys
      115          120          125

30     Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
      130          135          140

      Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
      145          150          155          160

      Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
      165          170          175

35     Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
      180          185          190

      Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
      195          200          205

40     Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
      210          215          220

      Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
      225          230          235          240

45     Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
      245          250          255

      Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
      260          265          270

50     Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
      275          280          285

```

55

Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 5 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 10 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 15 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ala Leu Gly Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 20 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

35 Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 40 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30
 45 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45
 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60
 55 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80

EP 0 568 833 A1

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95
 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 5 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
 115 120 125
 Arg Leu Tyr Gln Asn Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 130 135 140
 10 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
 145 150 155 160
 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
 165 170 175
 15 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 180 185 190
 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 20 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 25 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 30 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 35 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 40 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 45 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ile Ala Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 50 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415

55

EP 0 568 833.A1

Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

5

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 464 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

15

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

20

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

25

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

30

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

35

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
115 120 125

40

Arg Leu Tyr Gln Asn Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140

Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160

Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175

45

Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190

Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195 200 205

50

Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
210 215 220

55

EP 0 568 833 A1

Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 5 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 10 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 15 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 20 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 25 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ile Phe Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 30 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 50 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15

EP 0 568 833 A1

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

5 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

10 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

15 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
115 120 125

20 Arg Leu Tyr Gln Asn Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140

Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160

25 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175

Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190

30 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195 200 205

Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
210 215 220

35 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
225 230 235 240

Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
245 250 255

40 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
260 265 270

Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
275 280 285

45 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
290 295 300

Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

50 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

55

EP 0 568 833 A1

Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ile Val Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30
 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45
 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60
 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80
 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95
 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
 115 120 125
 Arg Leu Tyr Gln Asn Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 130 135 140
 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
 145 150 155 160

EP 0 568 833 A1

Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
 165 170 175
 5 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 180 185 190
 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 10 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 15 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 20 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 25 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 30 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 35 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ala Leu Gly Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 40 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 464 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

EP 0 568 833 A1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

	Met	Tyr	Ser	Asn	Val	Ile	Gly	Thr	Val	Thr	Ser	Gly	Lys	Arg	Lys	Val
	-32		-30					-25					-20			
5	Tyr	Leu	Leu	Ser	Leu	Leu	Leu	Ile	Gly	Phe	Trp	Asp	Cys	Val	Thr	Cys
	-15						-10					-5				
	His	Gly	Ser	Pro	Val	Asp	Ile	Cys	Thr	Ala	Lys	Pro	Arg	Asp	Ile	Pro
	1				5					10					15	
10	Met	Asn	Pro	Met	Cys	Ile	Tyr	Arg	Ser	Pro	Glu	Lys	Lys	Ala	Thr	Glu
				20					25					30		
	Asp	Glu	Gly	Ser	Glu	Gln	Lys	Ile	Pro	Glu	Ala	Thr	Asn	Arg	Arg	Val
			35					40					45			
15	Trp	Glu	Leu	Ser	Lys	Ala	Asn	Ser	Arg	Phe	Ala	Thr	Thr	Phe	Tyr	Gln
	50						55					60				
	His	Leu	Ala	Asp	Ser	Lys	Asn	Asp	Asn	Asp	Asn	Ile	Phe	Leu	Ser	Pro
	65					70				75						80
20	Leu	Ser	Ile	Ser	Thr	Ala	Phe	Ala	Met	Thr	Lys	Leu	Gly	Ala	Cys	Asn
					85					90					95	
	Asp	Thr	Leu	Gln	Gln	Leu	Met	Glu	Val	Phe	Lys	Phe	Asp	Thr	Ile	Ser
				100					105					110		
25	Glu	Lys	Thr	Ser	Asp	Gln	Ile	His	Phe	Phe	Phe	Ala	Lys	Leu	Asn	Cys
			115					120					125			
	Arg	Leu	Tyr	Gln	Lys	Ala	Asn	Lys	Ser	Ser	Lys	Leu	Val	Ser	Ala	Asn
	130						135					140				
30	Arg	Leu	Phe	Gly	Asp	Lys	Ser	Leu	Thr	Phe	Asn	Glu	Thr	Tyr	Gln	Asp
	145				150					155						160
	Ile	Ser	Glu	Leu	Val	Tyr	Gly	Ala	Lys	Leu	Gln	Pro	Leu	Asp	Phe	Lys
				165					170						175	
35	Glu	Asn	Ala	Glu	Gln	Ser	Arg	Ala	Ala	Ile	Asn	Lys	Trp	Val	Ser	Asn
			180					185						190		
	Lys	Thr	Glu	Gly	Arg	Ile	Thr	Asp	Val	Ile	Pro	Ser	Glu	Ala	Ile	Asn
			195					200					205			
40	Glu	Leu	Thr	Val	Leu	Val	Leu	Val	Asn	Thr	Ile	Tyr	Phe	Lys	Gly	Leu
	210					215						220				
	Trp	Lys	Ser	Lys	Phe	Ser	Pro	Glu	Asn	Thr	Arg	Lys	Glu	Leu	Phe	Tyr
	225				230					235						240
45	Lys	Ala	Asp	Gly	Glu	Ser	Cys	Ser	Ala	Ser	Met	Met	Tyr	Gln	Glu	Gly
				245					250						255	
	Lys	Phe	Arg	Tyr	Arg	Arg	Val	Ala	Glu	Gly	Thr	Gln	Val	Leu	Glu	Leu
			260					265						270		
50	Pro	Phe	Lys	Gly	Asp	Asp	Ile	Thr	Met	Val	Leu	Ile	Leu	Pro	Lys	Pro
		275						280					285			
	Glu	Lys	Ser	Leu	Ala	Lys	Val	Glu	Lys	Glu	Leu	Thr	Pro	Glu	Val	Leu

55

EP 0 568 833 A1

290 295 300

Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
355 360 365

His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
370 375 380

Ser Thr Ala Val Val Ile Phe Pro Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

EP 0 568 833 A1

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
 115 120 125
 Arg Leu Tyr Arg Asn Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 130 135 140
 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
 145 150 155 160
 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
 165 170 175
 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 180 185 190
 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ile Phe Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

55

EP 0 568 833 A1

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 464 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
115 120 125

Arg Leu Tyr Arg Gln Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140

Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160

Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175

Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190

Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195 200 205

Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
210 215 220

Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
225 230 235 240

EP 0 568 833 A1

Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 5 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 10 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 15 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 20 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 25 Ser Thr Ala Val Val Ile Phe Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 30 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 37:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 40 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:
 Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 45 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 50 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30

55

EP 0-568 833 A1

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
5 50 55 60

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
10 85 90 95

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

Glu Lys Thr Ser Asp Gln Ile His Phe Phe Ala Lys Leu Asn Cys
115 120 125

Gln Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140

Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160

Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175

Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190

Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195 200 205

Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
210 215 220

Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
225 230 235 240

Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
245 250 255

Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
260 265 270

Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
275 280 285

Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
290 295 300

Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
355 360 365

EP 0 568 833 A1

His Lys Ala Phe Leu Glu Val Asn Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ile Phe Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 464 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30
 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45
 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60
 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80
 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95
 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
 115 120 125
 Gln Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 130 135 140
 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
 145 150 155 160
 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
 165 170 175

EP 0 568 833 A1

Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 190 185 190
 5 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 10 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 15 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 20 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 25 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 30 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 35 Ser Thr Ala Val Val Ile Val Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 40 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 39:

45

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 464 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

50

- (ii) MOLECULE TYPE: protein

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

55

EP 0 568 833 A1

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

5 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

10 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

15 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

20 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

25 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
115 120 125

Gln Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140

30 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160

Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175

35 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190

Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195 200 205

40 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
210 215 220

Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
225 230 235 240

45 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
245 250 255

Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
260 265 270

50 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
275 280 285

Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
290 295 300

EP 0 568 833 A1

5 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

10 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
355 360 365

His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
370 375 380

15 Ser Thr Ala Val Val Ala Leu Gly Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

20 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 40:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Ile Pro Arg Ser Ile Pro
1 5 10 15

40 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

45 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

50 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

55

EP 0 568 833 A1

	Glu	Lys	Thr	Ser	Asp	Gln	Ile	His	Phe	Phe	Phe	Ala	Lys	Leu	Asn	Cys	
			115					120					125				
5	Arg	Leu	Tyr	Arg	Lys	Ala	Asn	Lys	Ser	Ser	Lys	Leu	Val	Ser	Ala	Asn	
		130					135					140					
	Arg	Leu	Phe	Gly	Asp	Lys	Ser	Leu	Thr	Phe	Asn	Glu	Thr	Tyr	Gln	Asp	
	145				150						155					160	
10	Ile	Ser	Glu	Leu	Val	Tyr	Gly	Ala	Lys	Leu	Gln	Pro	Leu	Asp	Phe	Lys	
				165						170					175		
	Glu	Asn	Ala	Glu	Gln	Ser	Arg	Ala	Ala	Ile	Asn	Lys	Trp	Val	Ser	Asn	
				180					185					190			
15	Lys	Thr	Glu	Gly	Arg	Ile	Thr	Asp	Val	Ile	Pro	Ser	Glu	Ala	Ile	Asn	
			195					200					205				
	Glu	Leu	Thr	Val	Leu	Val	Leu	Val	Asn	Thr	Ile	Tyr	Phe	Lys	Gly	Leu	
		210					215					220					
20	Trp	Lys	Ser	Lys	Phe	Ser	Pro	Glu	Asn	Thr	Arg	Lys	Glu	Leu	Phe	Tyr	
	225					230					235					240	
	Lys	Ala	Asp	Gly	Glu	Ser	Cys	Ser	Ala	Ser	Met	Met	Tyr	Gln	Glu	Gly	
				245						250					255		
25	Lys	Phe	Arg	Tyr	Arg	Arg	Val	Ala	Glu	Gly	Thr	Gln	Val	Leu	Glu	Leu	
			260						265					270			
	Pro	Phe	Lys	Gly	Asp	Asp	Ile	Thr	Met	Val	Leu	Ile	Leu	Pro	Lys	Pro	
			275					280					285				
30	Glu	Lys	Ser	Leu	Ala	Lys	Val	Glu	Lys	Glu	Leu	Thr	Pro	Glu	Val	Leu	
		290					295					300					
	Gln	Glu	Trp	Leu	Asp	Glu	Leu	Glu	Glu	Met	Met	Leu	Val	Val	His	Met	
	305				310					315						320	
35	Pro	Arg	Phe	Arg	Ile	Glu	Asp	Gly	Phe	Ser	Leu	Lys	Glu	Gln	Leu	Gln	
				325					330						335		
	Asp	Met	Gly	Leu	Val	Asp	Leu	Phe	Ser	Pro	Glu	Lys	Ser	Lys	Leu	Pro	
			340					345						350			
40	Gly	Ile	Val	Ala	Glu	Gly	Arg	Asp	Asp	Leu	Tyr	Val	Ser	Asp	Ala	Phe	
		355					360					365					
	His	Lys	Ala	Phe	Leu	Glu	Val	Asn	Glu	Glu	Gly	Ser	Glu	Ala	Ala	Ala	
		370				375					380						
45	Ser	Thr	Ala	Val	Val	Ile	Phe	Pro	Arg	Ser	Leu	Asn	Pro	Asn	Arg	Val	
	385					390					395					400	
	Thr	Phe	Lys	Ala	Asn	Arg	Pro	Phe	Leu	Val	Phe	Ile	Arg	Glu	Val	Pro	
				405					410					415			
50	Leu	Asn	Thr	Ile	Ile	Phe	Met	Gly	Arg	Val	Ala	Asn	Pro	Cys	Val	Lys	
			420					425						430			

55

EP 0 568 833 A1

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 464 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

10	Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val	-32 -30 -25 -20
	Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys	-15 -10 -5
15	His Gly Ser Pro Val Asp Ile Cys Thr Ala Ile Pro Arg Ser Ile Pro	1 5 10 15
	Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu	20 25 30
20	Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val	35 40 45
	Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln	50 55 60
25	His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro	65 70 75 80
	Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn	85 90 95
30	Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser	100 105 110
	Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys	115 120 125
35	Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn	130 135 140
	Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp	145 150 155 160
40	Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys	165 170 175
	Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn	180 185 190
45	Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn	195 200 205
	Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu	210 215 220
50	Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr	225 230 235 240

EP 0 568 833 A1

Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ile Val Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 His Gly Ser Pro Val Asp Ile Cys Thr Ala Ile Pro Arg Ser Ile Pro
 1 5 10 15
 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30
 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45

EP 0 568 833 A1

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

5 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

10 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
115 120 125

15 Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140

Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160

20 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175

Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190

25 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195 200 205

Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
210 215 220

30 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
225 230 235 240

Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
245 250 255

35 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
260 265 270

Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
275 280 285

40 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
290 295 300

Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
305 310 315 320

45 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
340 345 350

50 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
355 360 365

His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
370 375 380

55

EP 0 568 833 A1

Ser Thr Ala Val Val Ala Leu Gly Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415

Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Gln Leu Asn Cys
115 120 125

Arg Leu Tyr Gln Asn Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140

Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160

Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175

EP 0 568 833 A1

5 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 180 185 190

10 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205

 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220

15 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240

 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255

20 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270

 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285

25 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300

 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320

30 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335

35 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350

40 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365

45 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380

50 Ser Thr Ala Val Val Ile Phe Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400

55 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415

 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 464 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

EP 0 568 833 A1

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 5 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30
 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45
 10 Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60
 His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80
 15 Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95
 Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110
 20 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Gln Leu Asn Cys
 115 120 125
 Arg Leu Tyr Gln Asn Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 130 135 140
 25 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
 145 150 155 160
 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
 165 170 175
 30 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 180 185 190
 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 35 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 40 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 45 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 50 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320

55

Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350

Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365

His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380

Ser Thr Ala Val Val Ile Val Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400

Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415

Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 464 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
 100 105 110

EP 0 568 833 A1

Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Gln Leu Asn Cys
 115 120 125
 Arg Leu Tyr Gln Asn Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
 130 135 140
 Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
 145 150 155 160
 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
 165 170 175
 Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
 180 185 190
 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ala Leu Gly Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 46:

EP 0 568 833 A1

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 464 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110

Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Gln Leu Asn Cys
115 120 125

Gln Leu Tyr Gln Asn Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140

Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160

Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175

Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190

Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195 200 205

Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
210 215 220

Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
225 230 235 240

Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
245 250 255

55

EP 0 568 833 A1

Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ile Phe Pro Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 464 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20
 Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5
 His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15
 Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30
 Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45

EP 0 568 833 A1

	Trp	Glu	Leu	Ser	Lys	Ala	Asn	Ser	Arg	Phe	Ala	Thr	Thr	Phe	Tyr	Gln
	50						55					60				
5	His	Leu	Ala	Asp	Ser	Lys	Asn	Asp	Asn	Asp	Asn	Ile	Phe	Leu	Ser	Pro
	65					70					75					80
	Leu	Ser	Ile	Ser	Thr	Ala	Phe	Ala	Met	Thr	Lys	Leu	Gly	Ala	Cys	Asn
					85					90					95	
10	Asp	Thr	Leu	Gln	Gln	Leu	Met	Glu	Val	Phe	Lys	Phe	Asp	Thr	Ile	Ser
				100					105					110		
	Glu	Lys	Thr	Ser	Asp	Gln	Ile	His	Phe	Phe	Phe	Ala	Gln	Leu	Asn	Cys
			115					120					125			
15	Gln	Leu	Tyr	Gln	Asn	Ala	Asn	Lys	Ser	Ser	Lys	Leu	Val	Ser	Ala	Asn
	130						135					140				
	Arg	Leu	Phe	Gly	Asp	Lys	Ser	Leu	Thr	Phe	Asn	Glu	Thr	Tyr	Gln	Asp
	145					150					155					160
20	Ile	Ser	Glu	Leu	Val	Tyr	Gly	Ala	Lys	Leu	Gln	Pro	Leu	Asp	Phe	Lys
						165				170					175	
	Glu	Asn	Ala	Glu	Gln	Ser	Arg	Ala	Ala	Ile	Asn	Lys	Trp	Val	Ser	Asn
				180					185					190		
25	Lys	Thr	Glu	Gly	Arg	Ile	Thr	Asp	Val	Ile	Pro	Ser	Glu	Ala	Ile	Asn
			195					200					205			
	Glu	Leu	Thr	Val	Leu	Val	Leu	Val	Asn	Thr	Ile	Tyr	Phe	Lys	Gly	Leu
	210						215					220				
30	Trp	Lys	Ser	Lys	Phe	Ser	Pro	Glu	Asn	Thr	Arg	Lys	Glu	Leu	Phe	Tyr
	225					230					235					240
	Lys	Ala	Asp	Gly	Glu	Ser	Cys	Ser	Ala	Ser	Met	Met	Tyr	Gln	Glu	Gly
				245						250					255	
35	Lys	Phe	Arg	Tyr	Arg	Arg	Val	Ala	Glu	Gly	Thr	Gln	Val	Leu	Glu	Leu
			260						265					270		
	Pro	Phe	Lys	Gly	Asp	Asp	Ile	Thr	Met	Val	Leu	Ile	Leu	Pro	Lys	Pro
			275					280					285			
40	Glu	Lys	Ser	Leu	Ala	Lys	Val	Glu	Lys	Glu	Leu	Thr	Pro	Glu	Val	Leu
	290						295					300				
	Gln	Glu	Trp	Leu	Asp	Glu	Leu	Glu	Glu	Met	Met	Leu	Val	Val	His	Met
	305					310					315					320
45	Pro	Arg	Phe	Arg	Ile	Glu	Asp	Gly	Phe	Ser	Leu	Lys	Glu	Gln	Leu	Gln
				325						330					335	
	Asp	Met	Gly	Leu	Val	Asp	Leu	Phe	Ser	Pro	Glu	Lys	Ser	Lys	Leu	Pro
				340					345					350		
50	Gly	Ile	Val	Ala	Glu	Gly	Arg	Asp	Asp	Leu	Tyr	Val	Ser	Asp	Ala	Phe
			355					360					365			
	His	Lys	Ala	Phe	Leu	Glu	Val	Asn	Glu	Glu	Gly	Ser	Glu	Ala	Ala	Ala
	370						375					380				

EP 0 568 833 A1

Ser Thr Ala Val Val Ile Val Pro Arg Ser Leu Asn Pro Asn Arg Val
385 390 395 400
Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
405 410 415
Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
420 425 430

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 464 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
-32 -30 -25 -20
Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
-15 -10 -5
His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
1 5 10 15
Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
20 25 30
Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
35 40 45
Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
50 55 60
His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
65 70 75 80
Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
85 90 95
Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110
Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Gln Leu Asn Cys
115 120 125
Gln Leu Tyr Gln Asn Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
130 135 140
Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160
Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175
Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190

EP 0 568 833 A1

Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
 195 200 205
 5 Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
 210 215 220
 Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
 225 230 235 240
 10 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
 245 250 255
 Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
 260 265 270
 15 Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
 275 280 285
 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
 290 295 300
 20 Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
 305 310 315 320
 Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
 325 330 335
 25 Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 30 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 370 375 380
 Ser Thr Ala Val Val Ala Leu Gly Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 35 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 40 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 420 425 430

45

50

55

(2) INFORMATION FOR SEQ ID NO: 49:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

GTTTAGCGAC CGCGGAGCAA TCAC

(2) INFORMATION FOR SEQ ID NO: 50:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 33 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

GGGGTTTAGC GACCGCGGAA AAATCACAAC AGC

(2) INFORMATION FOR SEQ ID NO: 51:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

TAGCGAACGG CCGACAGCCA CAACAGCGGT

(2) INFORMATION FOR SEQ ID NO: 52:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

CAGCGGTACT GCCAGCTGCT TC

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

ACGGCCAGCA ATCGGAACAG CGGTACT

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

AATCACAACA AAGGTACTTG CAG

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

GTTTAGCGAA CGCGGAATAA TCACAACAGC

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

GTTTAGCGAA CGCGGACCAA TCACAACAG

29

(2) INFORMATION FOR SEQ ID NO: 57:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

GTTTAGCGAA CGCGGATAAA TCACAACAGC

30

(2) INFORMATION FOR SEQ ID NO: 58:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

GTTTAGCGAA CGCGGCCAAA TCACAACAGC

30

(2) INFORMATION FOR SEQ ID NO: 59:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

GTTTAGCGAA CGCGGAACAA TCACAACAG

29

(2) INFORMATION FOR SEQ ID NO: 60:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

5 TAGCGAACGG CCAATAGCCA CAACAGCGGT 30

(2) INFORMATION FOR SEQ ID NO: 61:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

15 TAGCGAACGG CCAAGAGCCA CAACAGCGGT 30

(2) INFORMATION FOR SEQ ID NO: 62:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 29 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

30 TAGCGAACGG CCAAGACCCA CAACAGCGG 29

(2) INFORMATION FOR SEQ ID NO: 63:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 34 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

45 GTTAGCGAA CGGGGAACAG CCACAACAGC GGTA 34

(2) INFORMATION FOR SEQ ID NO: 64:

50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 34 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

GTTTAGCGAA CGGGGAAAA GCACAACAGC GGTA

34

(2) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

GTTTAGCGAA CGCGGAAGAA TCACAACAGC

30

(2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 34 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

GTTTAGCGAA CGCGGATAAG CCACAACAGC GGTA

34

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 33 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

GTTTAGCGAA CGCGGCCAAG CCACAACAGC GGT

33

(2) INFORMATION FOR SEQ ID NO: 68:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 33 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

GTTTAGCGAA CGCGGCCAAA GCACAACCGA GGT

33

(2) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

GAAAGTCACC CTCTCGGGGT TTAGCGAAC

29

(2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

TTGAAAGTCA CCCTCCTCGG GTTTAGCGAA CG

32

(2) INFORMATION FOR SEQ ID NO: 71:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

TTGAAAGTCA CCCGTCGACG GTTTAGCGAA CG

32

(2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

CGGCAGTTCA GTTGGGCAAA GAAGAAG

27

(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

GGATTGTGTG GCGTTTTGAT AGAGTCGGCA

30

(2) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

GATAGAGTTG GCAGTTCAG

19

(2) INFORMATION FOR SEQ ID NO: 75:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

GGTGGCCTCC AGGATCTTCT G

21

(2) INFORMATION FOR SEQ ID NO: 76:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:

GGGATTCATG GGAATGGATC GTGGGATTGC TGTGCAGAT

39

(2) INFORMATION FOR SEQ ID NO: 77:

10 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:

20 GTTGGCTTTT TGATAGAGTC G

21

(2) INFORMATION FOR SEQ ID NO: 78:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:

TTTGTGGCG TTTGATAGA G

21

(2) INFORMATION FOR SEQ ID NO: 79:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:

45 TTTGTGGCT TGTCGATAGA G

21

(2) INFORMATION FOR SEQ ID NO: 80:

50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80:

TACATGGCCG AAGCTTCGTA ATCAT

25

(2) INFORMATION FOR SEQ ID NO: 81:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:

CAAAGAATAA GATCTTATTA CTTAACACA

29

Claims

1. A human antithrombin III (AT III) mutant obtained by subjecting human AT III to mutation, which has human AT III amino acid sequence described below except that an amino acid(s) mutates into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions, the 125- to 133-positions and the 384- to 398-positions:

human AT III amino acid sequence

5

Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg Lys Val
 -32 -30 -25 -20

10

Tyr Leu Leu Ser Leu Leu Leu Ile Gly Phe Trp Asp Cys Val Thr Cys
 -15 -10 -5

15

His Gly Ser Pro Val Asp Ile Cys Thr Ala Lys Pro Arg Asp Ile Pro
 1 5 10 15

Met Asn Pro Met Cys Ile Tyr Arg Ser Pro Glu Lys Lys Ala Thr Glu
 20 25 30

20

Asp Glu Gly Ser Glu Gln Lys Ile Pro Glu Ala Thr Asn Arg Arg Val
 35 40 45

25

Trp Glu Leu Ser Lys Ala Asn Ser Arg Phe Ala Thr Thr Phe Tyr Gln
 50 55 60

His Leu Ala Asp Ser Lys Asn Asp Asn Asp Asn Ile Phe Leu Ser Pro
 65 70 75 80

30

Leu Ser Ile Ser Thr Ala Phe Ala Met Thr Lys Leu Gly Ala Cys Asn
 85 90 95

35

40

45

50

55

EP 0 568 833 A1

Asp Thr Leu Gln Gln Leu Met Glu Val Phe Lys Phe Asp Thr Ile Ser
100 105 110
5 Glu Lys Thr Ser Asp Gln Ile His Phe Phe Phe Ala Lys Leu Asn Cys
115 120 125
Arg Leu Tyr Arg Lys Ala Asn Lys Ser Ser Lys Leu Val Ser Ala Asn
10 130 135 140
Arg Leu Phe Gly Asp Lys Ser Leu Thr Phe Asn Glu Thr Tyr Gln Asp
145 150 155 160
15 Ile Ser Glu Leu Val Tyr Gly Ala Lys Leu Gln Pro Leu Asp Phe Lys
165 170 175
Glu Asn Ala Glu Gln Ser Arg Ala Ala Ile Asn Lys Trp Val Ser Asn
180 185 190
20 Lys Thr Glu Gly Arg Ile Thr Asp Val Ile Pro Ser Glu Ala Ile Asn
195 200 205
Glu Leu Thr Val Leu Val Leu Val Asn Thr Ile Tyr Phe Lys Gly Leu
25 210 215 220
Trp Lys Ser Lys Phe Ser Pro Glu Asn Thr Arg Lys Glu Leu Phe Tyr
225 230 235 240
30 Lys Ala Asp Gly Glu Ser Cys Ser Ala Ser Met Met Tyr Gln Glu Gly
245 250 255
Lys Phe Arg Tyr Arg Arg Val Ala Glu Gly Thr Gln Val Leu Glu Leu
35 260 265 270
Pro Phe Lys Gly Asp Asp Ile Thr Met Val Leu Ile Leu Pro Lys Pro
275 280 285
40 Glu Lys Ser Leu Ala Lys Val Glu Lys Glu Leu Thr Pro Glu Val Leu
290 295 300
Gln Glu Trp Leu Asp Glu Leu Glu Glu Met Met Leu Val Val His Met
45 305 310 315 320
Pro Arg Phe Arg Ile Glu Asp Gly Phe Ser Leu Lys Glu Gln Leu Gln
325 330 335

50

55

Asp Met Gly Leu Val Asp Leu Phe Ser Pro Glu Lys Ser Lys Leu Pro
 340 345 350
 5 Gly Ile Val Ala Glu Gly Arg Asp Asp Leu Tyr Val Ser Asp Ala Phe
 355 360 365
 His Lys Ala Phe Leu Glu Val Asn Glu Glu Gly Ser Glu Ala Ala Ala
 10 370 375 380
Ser Thr Ala Val Val Ile Ala Gly Arg Ser Leu Asn Pro Asn Arg Val
 385 390 395 400
 15 Thr Phe Lys Ala Asn Arg Pro Phe Leu Val Phe Ile Arg Glu Val Pro
 405 410 415
 Leu Asn Thr Ile Ile Phe Met Gly Arg Val Ala Asn Pro Cys Val Lys
 20 420 425 430

2. The human AT III mutant as claimed in Claim 1, wherein said another amino acid(s) is selected from the group consisting of Ala, Gly, Trp, Pro, Leu, Val, Phe, Tyr, Ile, Glu, Ser, Gln, Asn and Arg.
3. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions and that an amino acid(s) mutates into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 125- to 133-positions.
4. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions and that an amino acid(s) mutates into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions and the 41- to 47-positions.
5. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions and that an amino acid(s) mutates into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions and the 125- to 133-positions.
6. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions and that an amino acid(s) mutates into another amino acid(s) at a region(s) selected from the group consisting of the 41- to 47-positions and the 125- to 133-positions.
7. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 11- to 14-positions and that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions.
8. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 41- to 47-positions and that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions.
9. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 125- to 133-positions and that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions.

10. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that an amino acid(s) mutates into another amino acid(s) at the 384- to 398-positions.
- 5 11. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that an amino acid(s) at the 384- to 398-positions mutates into another amino acid(s) selected from the group consisting of Ala, Pro, Leu, Val, Gly, Arg, Glu and Phe and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 125- to 133-positions.
- 10 12. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that an amino acid(s) at the 390- to 392-positions mutates into another amino acid(s) selected from the group consisting of Ala, Pro, Leu, Val and Phe and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 125- to 133-positions.
- 15 13. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that Gly at the 392-position mutates into Pro and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 125- to 133-positions.
- 20 14. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that a mutation selected from the group consisting of a mutation of Ile at the 390- position into Ala, a mutation of Ala at the 391- position into Phe, Val or Leu and a mutation of Gly at the 392-position into Pro is present and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 125- to 133-positions.
- 25 15. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that a mutation selected from the group consisting of a mutation of Ala at the 384- position into Gly, a mutation of Ala at the 387- position into Phe, a mutation of Val at the 389-position into Pro, a mutation of Pro at the 397- position into Arg and a mutation of Asn at the 398-position into Glu or Arg is present and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 125- to 133-positions.
- 30 16. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that a mutation selected from the group consisting of a mutation of Lys at the 11- position into Ile, a mutation of Asp at the 14- position into Ser is present and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 41- to 47-positions, the 125- to 133-positions and the 384- to 398-positions.
- 35 17. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that a mutation selected from the group consisting of a mutation of Lys at the 11- position into Ile and a mutation of Asp at the 14- position into Ser, and, another mutation selected from the group consisting of a mutation of Ile at the 390- position into Ala, a mutation of Ala at the 391- position into Phe, Val or Leu and a mutation of Gly at the 392-position into Pro are present, and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 41- to 47-positions and the 125- to 133-positions.
- 40 18. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that a mutation selected from the group consisting of a mutation of Lys at the 125- position into Gln, a mutation of Arg at the 129- position into Gln, a mutation of Arg at the 132-position into Gln and a mutation of Lys at the 133- position into Asn or Gln is present and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions, the 41- to 47-positions and the 384- to 398-positions.
- 45 19. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that a mutation selected from the group consisting of a mutation of Lys at the 125- position into Gln, a mutation of Arg at the 129- position into Gln, a mutation of Arg at the 132-position into Gln and a

5 mutation of Lys at the 133- position into Asn or Gln, and, another mutation selected from the group consisting of a mutation of Ile at the 390- position into Ala, a mutation of Ala at the 391- position into Phe, Val or Leu and a mutation of Gly at the 392-position into Pro are present, and that an amino acid(s) may mutate into another amino acid(s) at a region(s) selected from the group consisting of the 11- to 14-positions and the 41- to 47-positions.

20. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that Gly at the 392-position mutates into Pro.
- 10 21. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that Ala-Gly at the 391- to 392-positions mutates into Phe-Pro.
22. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that Ile-Ala at the 390- to 391-positions mutates into Ala-Leu.
- 15 23. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that Lys at the 125-position mutates into Gln and Ala-Gly at the 391- to 392-positions mutates into Phe-Pro.
- 20 24. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that Arg-Lys at the 132- to 133-positions mutates into Gln-Asn and Ile-Ala at the 390- to 391-positions mutates into Ala-Leu.
- 25 25. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that Arg-Lys at the 132- to 133-positions mutates into Gln-Asn and Ala-Gly at the 391- to 392-positions mutates into Phe-Pro.
- 30 26. The human AT III mutant as claimed in Claim 1, which has human AT III amino acid sequence except that Lys at the 133-position mutates into Asn and Ala-Gly at the 391- to 392-positions mutates into Phe-Pro.
27. A DNA coding for the human AT III mutant as claimed in Claim 1.
28. An expressible vector which has a DNA containing part or the whole of the DNA sequence coding for the human AT III mutant as claimed in Claim 1.
- 35 29. A transformant which is obtained by subjecting host cells to transformation with the expressible vector as claimed in Claim 28.
- 40 30. The transformant as claimed in Claim 29, wherein the host cells are Escherichia coli or animal cells.
31. A method for producing a human AT III mutant which comprises incubating the transformant as claimed in Claim 30 and recovering the human AT III mutant produced by the transformant from the culture.
- 45 32. A drug composition for thrombotic disorders which contains the human AT III mutant as claimed in Claim 1 and pharmaceutically acceptable carriers.
33. A use of the human AT III mutant as claimed in Claim 1 for the making of a medicament for treating thrombotic disorders.

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9





Fig. 10





European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 93 10 5829

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
D,X	WO-A-9 100 291 (AKZO N.V.) * the whole document * ---	1,2, 27-33	C07K15/00 A61K37/64 C12N15/15
D,X	EP-A-0 384 122 (BEHRINGWERKE AG) * the whole document * ---	1,2, 27-33	
A	EP-A-0 424 351 (WASHINGTON UNIVERSITY) * abstract; claims 1-10 * -----	1,27-33	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			C07K
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 12 JULY 1993	Examiner GURDJIAN D.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 01.92 (F0401)

1. The first part of the document is a letter from the President of the United States to the Congress, dated January 1, 1861. It is a very important document, as it sets out the policy of the new administration. The President states that he is committed to the principles of liberty and justice for all, and that he will work to maintain the Union. He also mentions the issue of slavery, which was a major point of contention at the time.

2. The second part of the document is a report from the Secretary of the Treasury, dated January 1, 1861. It provides a detailed account of the financial state of the country. The report mentions the national debt, which had increased significantly since the end of the Civil War. It also discusses the various sources of revenue, including taxes and customs duties.

3. The third part of the document is a report from the Secretary of the Interior, dated January 1, 1861. It discusses the various land claims and the process of land distribution. The report mentions the importance of land for the development of the country, and the need to ensure that the land is distributed fairly.

4. The fourth part of the document is a report from the Secretary of the Navy, dated January 1, 1861. It discusses the state of the Navy, including the number of ships and the personnel. The report mentions the need to modernize the Navy, and the importance of maintaining a strong naval presence.

5. The fifth part of the document is a report from the Secretary of the War, dated January 1, 1861. It discusses the state of the Army, including the number of troops and the equipment. The report mentions the need to improve the Army, and the importance of maintaining a strong military presence.

6. The sixth part of the document is a report from the Secretary of the State, dated January 1, 1861. It discusses the state of the foreign relations of the United States. The report mentions the various treaties and agreements that the United States has entered into, and the importance of maintaining good relations with other countries.

7. The seventh part of the document is a report from the Secretary of the Education, dated January 1, 1861. It discusses the state of the public education system. The report mentions the need to improve the quality of education, and the importance of ensuring that all children have access to education.

8. The eighth part of the document is a report from the Secretary of the Agriculture, dated January 1, 1861. It discusses the state of the agricultural industry. The report mentions the various crops and livestock that are raised in the United States, and the importance of supporting the agricultural sector.

9. The ninth part of the document is a report from the Secretary of the Commerce, dated January 1, 1861. It discusses the state of the commercial industry. The report mentions the various goods and services that are produced in the United States, and the importance of supporting the commercial sector.

10. The tenth part of the document is a report from the Secretary of the Labor, dated January 1, 1861. It discusses the state of the labor market. The report mentions the various occupations and the wages that are paid to workers, and the importance of supporting the labor sector.